Treatment with systemic immunostimulatory agents (including, but not limited to, interferon-alpha or interleukin-2 [aldesleukin]) within 6 weeks prior to cycle 1, day 1.

Patient with advanced or metastatic solid tumor and has disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment that meets the following requirements for the part of the study they will participate in:

Must have failed treatment with one regimen containing a fluoropyrimidine, oxaliplatin with or without bevacizumab for metastatic disease. All patients must have received a minimum of 6 weeks of the first-line regimen that included bevacizumab (if applicable), oxaliplatin and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic progression during or < 6 months after the last dose of first-line therapy.

Women who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.

Prior treatment with napabucasin.

The patient must be willing to undergo a biopsy prior to treatment

Prior treatment with TRC105

Current treatment or participation on another therapeutic clinical trial

Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor size

Prior enrollment in an enfortumab vedotin study or prior treatment with other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).

PRIOR TREATMENT

Patients must have adequate hematologic, liver and renal function =< 28 days prior to randomization\r\n* NOTE: It is preferred that laboratory values for eligibility be assessed after the last dose of prior treatment, especially in cases where most-recent treatment prior to study entry is chemotherapy

Patients may not be receiving Coumadin while on treatment; other anticoagulants are allowed

No currently active other malignancies which require systemic treatment

Any prior chemotherapy or androgen receptor (AR)-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone acetate, ketoconazole, or enzalutamide); previous treatment with radium-223 or sipuleucel-T is allowed

Patients with prior treatment with PLD

Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1

No more than 3 prior systemic treatment regimens for advanced PNET

Treatment with systemic immunostimulatory medications (including, but not limited to interferon [IFN]-alpha or interleukin [IL]-2 within 42 days prior to randomization

Patient has not had prior treatment with blinatumomab

Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted

Patients with recurrent carcinoma of the vulva regardless of previous treatment

Previous steroid treatment and/or radiation treatment is not allowed unless it is for the emergent management of a mediastinal mass; emergent steroid treatment and/or radiation treatment should stop once protocol therapy is initiated

No prior treatment with high-dose chemotherapy (defined as treatment utilizing stem cell rescue)

No prior treatment with TIP with the exception when given as a bridge to treatment on protocol for patients with rapidly progressive disease who cannot wait to complete the eligibility screening process; only one cycle is allowed

Prior treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) is allowed, provided the following is met: minimum of 6 weeks prior to cycle 1, day 1

Previous treatment with brentuximab vedotin will be allowed if it was done 6 months prior to enrollment and was not refractory to or had progressive disease (PD) on brentuximab vedotin (BV)

Prior treatment with brentuximab in the last 6 months or had refractory or progressive disease to prior BV treatment

At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity

Prior treatment with PM01183, topotecan or anthracyclines.

Current treatment on another therapeutic clinical trial

Prior treatment with alisertib

Initiation of bisphosphonate/denosumab therapy during protocol treatment; patients on stable doses of bisphosphonates or denosumab which have been started no less than 4 weeks prior to treatment start may continue on this medication; NOTE: initiation of bisphosphonate/denosumab therapy will be allowed for the treatment of osteoporosis or prevention of skeletal-related events (SRE) during protocol treatment

Prior treatment with PM01183 or trabectedin

Uncontrolled ascites requiring weekly large-volume paracentesis for 2 consecutive weeks prior to initiation of study treatment

For Cohort E only: prior treatment with fulvestrant is prohibited

Clinical indication for treatment with azacitidine for MDS or AML.

-  Treatment with an immunomodulatory agent within 4 weeks prior to first administration of BI 836858.

prior treatment failure with at least two cycles of hypomethylating agent.

Prior treatment with an anti-CD123-directed agent

Prior treatment with immunotherapy

Patients must not have received prior treatment with inotuzumab ozogamicin; previous treatment with other anti-CD22 antibodies must have been completed at least 90 days prior to registration

Preceding line of treatment included response to anti-androgen, progression documented after withdrawal of the anti-androgen.

Treatment before study with

Treatment before study with

Patients who have had any prior radiotherapy to the treatment site(s)

Prior pomalidomide treatment (for patients on the pomalidomide arm)

Prior treatment with systemic chemotherapy for bladder cancer. (Prior intravesical treatment is allowed.)

Other prior malignancy active within the previous 2 years except for local or organ-confined early stage cancer that has been definitively treated with curative intent or does not require treatment, does not require ongoing treatment, has no evidence of active disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the endpoints of the study.

Prior therapy with intravesical Bacillus Calmette-Guerin (BCG) within 6 weeks of treatment.

Receipt of previous approved or investigative immune modulatory agent within 28 days of receiving the first dose of treatment;

Prior treatment with idelalisib;

Past, current or planned treatment with tumor treatment fields; oncolytic viral treatment; or prior exposure to an investigational agent or device within 28 days of receiving the first dose of treatment;

Prior treatment with a BCMA-targeted agent

Any prior ALK inhibition (for screening and treatment phases)

Prior therapy with BRAF/MEK agents within 3 weeks prior to first day of study treatment (for treatment phase)

Any other systemic or regional anticancer therapy (cytotoxic chemotherapy, embolization) within 3 weeks or 1 cycle length, whichever is shorter, prior to first day of study treatment (for treatment phase)

Prior RT or clinically relevant major surgery (e.g. craniotomy, metastasectomy) within 2 weeks prior to first day of study treatment (for treatment phase)

Any serious, active infection at the time of treatment such as bacteremia (for treatment phase)

Prior treatment with venetoclax

Prior treatment with more than 1 cycle of azacitidine or decitabine.

Treatment-naive participants with AML who are >/=75 years old

All Cohort A Dose Escalation Participants:\r\n* Prior hormonal therapy: Participants may have received any number of previous endocrine / hormonal lines of therapy in the metastatic setting (including prior fulvestrant), as long as the last dose is >= 14 days prior to first dose of study treatment\r\n* Prior biologics / investigational therapy: Prior therapy with biologics and investigational drugs is allowed, as long as the last dose is >= 21 days prior to first dose of study treatment\r\n* Prior CDK4/6 inhibition is allowed; participants who have had prior ribociclib must have received treatment at full-dose without any dose reductions; the last dose is required to be >= 21 days prior to first dose of study treatment\r\n* Treatment with prior PD1/PDL1/CTLA4 inhibitors is prohibited\r\n* Prior radiotherapy: Participants may have received radiotherapy for palliative purposes but must have completed treatment ? 14 days prior to first dose of study treatment and not be experiencing grade > 1 treatment-related toxicities\r\n* Evaluable or measurable disease by RECIST 1.1

Cohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Prior CDK4/6 inhibition is allowed; participants who have had prior ribociclib must have received treatment at full-dose without any dose-reductions; the last dose is required to be >= 21 days prior to first study treatment

Cohort B Safety Run-In (Ribociclib + PDR001 + Fulvestrant): Prior radiotherapy;\r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= 14 days prior to first dose of study treatment and not be experiencing > grade 1 treatment related toxicities

Cohort A Dose Expansion (Ribociclib + PDR001): Prior radiotherapy: \r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= 14 days prior to first dose of study treatment and not be experiencing grade > 1 treatment-related toxicities

Expansion Cohort B (Ribociclib + PDR001 + Fulvestrant): Prior radiotherapy:\r\n* Participants may have received radiotherapy for palliative purposes but must have completed treatment >= 14 days prior to first dose of study treatment and not be experiencing grade > 1 treatment-related toxicities

Treatment-related, immune-mediated adverse events associated with prior immunotherapeutic agents

Prior treatment with a monoclonal antibody or chimeric antigen receptor T cell (CAR-T) infusion for the treatment of AML (CD33 or other target).

For Groups B or C patients must be off conventional therapy for at least 1 week prior to receiving treatment on this study

Inclusion Criteria:\n\n        Specific criteria for patients who continue treatment as well as safety and survival\n        follow-up in the extension study:\n\n          -  Eligible for continuing or crossing over to atezolizumab-based therapy at the time of\n             the parent-study closure as per the parent study or eligible for continuing the\n             comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the\n             parent-study closure as per the parent study\n\n          -  First dose of study treatment in the extension study will be received within the\n             treatment interruption period allowed by the parent study\n\n          -  Continue to benefit from atezolizumab-based study treatment or from the comparator at\n             the time of parent-study closure as assessed by the investigator\n\n          -  Negative serum pregnancy test within 7 days prior to start of study treatment in women\n             of childbearing potential\n\n        Specific criteria for patients who do not continue treatment in the extension study and/or\n        receive commercially available atezolizumab (Tecentriq) outside this extension study and\n        continue safety and survival follow-up only in the extension study:\n\n        - Discontinuation of atezolizumab-based therapy in parent study and in survival follow up\n        at the time of parent study closure, or eligible for continuing or crossing over to\n        atezolizumab-based therapy as per the parent protocol and have access to commercially\n        available atezolizumab (Tecentriq) outside this extension study at the time of the\n        parent-study closure\n\n        Exclusion Criteria:\n\n        Specific criteria for patients who continue treatment as well as safety and survival\n        follow-up in the extension study:\n\n          -  Meet of any of the study treatment discontinuation criteria specified in the parent\n             study at the time of enrollment in the extension study\n\n          -  Study treatment is commercially marketed in the patient's country for the patient\n             specific disease and is accessible to the patient\n\n          -  Time between the last dose of treatment received in parent study and first dose in\n             extension study is longer than the interruption period allowed in the parent study\n\n          -  Treatment with any anti-cancer treatment (other than treatment permitted in the parent\n             study) during the time between last treatment in the parent study and the first dose\n             of study treatment in the extension study\n\n          -  Permanent discontinuation of atezolizumab for any reason during the parent study or\n             during the time between last treatment in the parent study and the first dose of study\n             treatment in the extension study (if applicable)\n\n          -  Any unresolved or irreversible toxicities during the parent study that required\n             permanent discontinuation of study treatment, in accordance to the parent study or\n             local prescribing information\n\n          -  Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to\n             (<=) 1 from the parent study or during the time between last treatment in the parent\n             study and the first dose of study treatment in the extension study\n\n          -  Any serious uncontrolled concomitant disease that would contraindicate the use of\n             study treatment at the time of the extension study or that would place the participant\n             at high risk for treatment-related complications\n\n          -  Concurrent participation in any therapeutic clinical trial (other than the parent\n             study)\n\n        Specific criteria for patients who do not continue treatment in the extension study and/or\n        receive commercially available atezolizumab (Tecentriq) outside this extension study and\n        continue safety and survival follow-up only in the extension study:\n\n        - Discontinuation of comparator in parent study and in survival follow-up at the time of\n        parent study closure

Clinical conditions requiring treatment with oral or parenteral anticoagulants or antiplatelet agents unless treatment can be discontinued 7 days (or 5 half-lives) prior to initiation of study treatment (except used as flushes for indwelling catheters)

Refractory to or relapsed after at least 1 prior treatment line.

Prior treatment with MM-310

Refractory to prior brentuximab vedotin (i.e. progression while on treatment)

Ongoing treatment with an anticancer agent.

Previous treatment with Apatinib.

Patients on bisphosphonates may continue receiving bisphosphonate therapy during study treatment

Patients must be willing to donate a small amount of whole blood prior to treatment and during treatment for laboratory analysis

Docetaxel monotherapy is a reasonable treatment in the judgement of the Investigator

Prior treatment with CD47 or signal regulatory protein alpha (SIRP?) targeting agents.

Resolution of treatment-related toxicities

Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1

Prior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways.

Subjects have no known curative treatment.

Ongoing treatment with an anticancer agent for MDS not contemplated in this protocol.

Previous treatment with palbociclib

Patients who have had previous treatment with bevacizumab

Are eligible for a curative treatment option.

Previous progression (radiographic or PSA progression) while on treatment with abiraterone, enzalutamide, or a combination.

Recovery from prior treatment-related toxicities

Prior treatment with regorafenib

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study

Cohort A:\r\n* Prior treatment with at least one regimen containing trastuzumab and taxane\r\n* No prior treatment with T-DM1 that was discontinued due to disease progression or toxicity\r\n* No more than 4 prior lines of therapy in the metastatic setting

Patients have had no previous treatment except corticosteroid use

Research participants with any concomitant significant medical illness that in the investigator’s opinion cannot be adequately controlled with appropriate therapy, or that would impair the evaluation of side effects related to this treatment, alter drug metabolism or the tolerance to this treatment

For obinutuzumab in combination with polatuzumab vedotin and lenalidomide (G + Pola + Len) treatment group: R/R FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator

Must be capable of treatment without general anesthesia

Prior treatment with the same agent or combination as the study drug; prior treatment in monotherapy when treated in one of the combination arms in the study is allowed

No prior systemic treatment is allowed, except for subjects in the phase I cohort who are permitted one prior systemic treatment

Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment

Hematologic growth factors are not allowed at Screening or during the first cycle of treatment.

Any prior treatment with taxotere or carboplatin

Treatment with clarithromycin, anti-myeloma therapy including investigational agents or plasmapheresis within 15 days prior to treatment in this study

Previous treatment with ixazomib or pomalidomide

Prior treatment with radiopharmaceutical including radium-223, strontium-89, or samarium-153

Prior treatment with 3rd generation TKI

Ongoing treatment with an anticancer agent not contemplated in this protocol.

Suitable for treatment with nivolumab per package insert

Prior treatment with a cancer vaccine for this indication

Prior treatment with any methotrexate containing systemic regimen within 1 year (excluding intrathecal methotrexate)

Serum calcium (corrected for albumin) level at or below the ULN range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with standard treatment) prior to study therapy initiation

Radiotherapy within one week prior to starting study treatment.

Lesion must be sonographically visible at the time of treatment.

Parts H, and I: Must be able and willing to undergo mandatory tumor biopsies prior to study treatment and at the time of discontinuation from study treatment.

Participants may have either extensive or limited cGVHD requiring systemic treatment

Any previous autologous EBV specific T cell treatment.

Previous treatment for ALL, except for prior steroids and/or hydroxyurea

Previous androgen suppression therapy is allowed if it was completed at least 3 months prior to initiation of study treatment

Patients who have had previous treatment with tivozanib are excluded

Patients who have received investigational or licensed drugs that target vascular endothelial growth factor [VEGF] or VEGF receptors/pathways (such as bevacizumab, sorafenib, pazopanib, sunitinib, axitinib, cabozantinib, etc.) for the treatment of recurrent cancer are not eligible; exceptions: prior treatment with bevacizumab in the up-front or maintenance setting is allowed, provided the patient had a favorable response to bevacizumab; favorable response is defined as having had a disease free interval of > 6 months following completion of a bevacizumab-containing regimen; if questions, contact the principal investigator (PI)

Participants who have received treatment with a TKI within 7 days of the first dose of study treatment; (an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by principal investigator and the investigator

Prior treatment with ziv-aflibercept is not allowed

Previous imatinib treatment should be permanently discontinued within 4 days prior randomisation and patient should have recovered from potential toxicity related to imatinib

Patients who have had previous treatment with nintedanib

Evidence of an active lesion including: plexiform neurofibroma, malignant peripheral nerve sheath tumor, or other cancer requiring concurrent treatment with chemotherapy or radiation therapy; patients not requiring treatment for these lesions are eligible for this protocol

Use of hematopoietic growth factors within 4 weeks of treatment

Prior treatment with 89-Strontium or 153-Samarium containing compounds (e.g. Metastron®, Quadramet®)

Prior treatment with cabozantinib

Patient must not have had prior treatment with paclitaxel or nab-paclitaxel

No prior treatment with ONC201.

Participants must not have more than 5 new or progressive lesions in the brain requiring SRS treatment (greater than 5 total brain lesions are allowed as long as no more than 5 lesions require SRS treatment)

Have received treatment with a therapeutic antibody less than 4 weeks before the first dose of AG-270. A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of AG-270 may be permitted in subjects with rapidly progressive or aggressive subtypes of lymphoma following discussion with the medical monitor.

Lesion amenable to treatment with both PLA and HIGRT; for PLA treatment this requires the lesion be visible via ultrasound and/or non-contrast CT or feasible per treating physician

Prior treatment with paclitaxel as part of definitive therapy regimen is acceptable, provided the patient is not intolerant of paclitaxel.

Participants with prostate cancer who are unable to interrupt treatment with ketoconazole; ketoconazole treatment must be discontinued 2 weeks prior to first dose of study medication and is not allowed during Cycle 1, but may be used in the optional extension phase.

The disease should be progressing/relapsed during or after the previous treatment.

Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1

Any investigational agents, anti-cancer monoclonal antibody, anti-cancer therapeutic vaccine, immunostimulant (e.g. IL-2) or study drugs from a previous clinical study within 4 weeks of the first dose of mRNA-4157 or pembrolizumab (note only a 2 week wash out is required from prior pembrolizumab treatment)

Participants must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study

Prior investigational drugs or interventions for invasive breast cancer treatment within 6 months before registration are not allowed; prior participation in window-of-opportunity trials without therapeutic intent is allowed if intervention is no more than 3 weeks in duration

No prior treatment for CAH/EIN/EC

Subject must appropriately be able to complete Screening assessments before beginning treatment for DLBCL, in the judgement of the Investigator. For subjects with bulky disease, B-symptoms, compressive disease, elevated bilirubin due to lymphoma, rapidly progressing adenopathies, or worsening performance status, pre-phase treatment with up to 100 mg/day prednisone, or equivalent, for a maximum of 10 days is permitted prior to beginning the treatment period, at the discretion of the Investigator. A washout period is not required, however, the Screening positron emission tomography (PET), CT, tumor biopsy (if needed), and bone marrow biopsy (if needed) should be completed before initiating corticosteroids.

Prior treatment with any immunotherapy

Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment

Agrees to undergo a pretreatment and a post-treatment biopsy.

Serum calcium (corrected for albumin) level at or below the ULN (treatment of hypercalcemia is allowed and participant may enroll if hypercalcemia returns to normal with standard treatment).

Inclusion Criteria:\n\n        Arms 1 and 2 Participants:\n\n          -  Has any histologically or cytologically confirmed advanced/metastatic solid tumor by\n             pathology report and has received, or have been intolerant to all treatment known to\n             confer clinical benefit. Solid tumors and lymphomas of any type are eligible for\n             enrollment. For cutaneous T-cell lymphoma (CTCL), histopathological diagnosis should\n             be confirmed in a skin biopsy representative of disease.\n\n          -  Have Stage III or Stage IV disease that is not surgically resectable. Stage IIB\n             (T3N0M0B0-1) CTCL participants are eligible.\n\n        Arm 3 Participants:\n\n        -Has metastatic liver and/or liver lesion involvement that does not exceed one third of the\n        total liver volume in participants to be treated by liver IT injection. Hepatocellular\n        carcinoma participants are excluded from eligibility of IT liver injection.\n\n        All Participants:\n\n          -  Stage III or Stage IV disease that is not surgically resectable.\n\n          -  Has ?1 injectable lesion that is amenable to injection and biopsy via visual\n             inspection for a cutaneous lesion, or via ultrasound guidance for a subcutaneous\n             lesion.\n\n          -  Has ?1 discrete, distant noninjected lesion that is amenable to biopsy via visual\n             inspection or amenable to biopsy via image guidance.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n\n          -  Demonstrates adequate organ function.\n\n          -  If of childbearing potential, must agree to use adequate contraception during the\n             treatment period and for at least 120 days after the last dose of study treatment.\n\n        Exclusion Criteria:\n\n          -  History of a second malignancy, unless potentially curative treatment has been\n             completed, with no evidence of malignancy for 2 years (except for successful\n             definitive resection of basal cell carcinoma of the skin, superficial bladder cancer,\n             or in situ cervical cancer).\n\n          -  Clinically active central nervous system metastases and/or carcinomatous meningitis.\n\n          -  Severe hypersensitivity reaction to treatment with a monoclonal antibody (mAb).\n\n          -  Active autoimmune disease that has required systemic treatment in the past 2 years.\n\n          -  History of vasculitis.\n\n          -  Active infection requiring therapy.\n\n          -  History of (noninfectious) pneumonitis that required steroids or current pneumonitis.\n\n          -  Undergone prior allogeneic hematopoietic stem cell transplantation within the last 5\n             years.\n\n          -  Known human immunodeficiency virus (HIV) and/or Hepatitis B or C infection.\n\n          -  Pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of the study.\n\n          -  Not fully recovered from any effects of major surgery, and is free of significant\n             detectable infection.\n\n          -  Had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2\n             weeks for palliative radiation) prior to the first dose of study treatment, or has not\n             recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) Grade\n             1 from the AEs due to cancer therapeutics administered >4 weeks earlier.\n\n          -  Been treated within 2 weeks of Cycle 1 Day1 with any of the following: strong/moderate\n             Cytochrome P450 2C9 (CYP2C9) inhibitors, such as: amiodarone, felbamate, fluconazole,\n             miconazole, piperine, oxandrolone, fluorouracil and its derivatives (combination drug\n             tegafur/gimeracil/oteracil [TS-1], Uftoral [UFT], tegafur, carmofur, doxifluridine,\n             capecitabine), sulfaphenazole, cyclosporine, bucurol, tienilic acid; UGT1A3 inhibitors\n             (including ritonavir, quinidine, probenecid, and valproic acid); or strong carbonyl\n             reductase (CBR) inhibitors (including quercetin, menadione, glycyrrhetinic acid, and\n             flufenamic acid).\n\n          -  Currently participating and receiving study therapy or has participated in a study of\n             an investigational agent and has received study therapy or has used an investigational\n             device within 28 days of administration of MK 2118.\n\n          -  Expected to require any other form of antineoplastic therapy while on study.\n\n          -  On chronic systemic steroid therapy in excess of replacement doses (prednisone ?10\n             mg/day is acceptable), or on any other form of immunosuppressive medication. For CTCL,\n             continued use of either prednisone ?10 mg/day or continued use of topical steroids is\n             acceptable.\n\n          -  Received a live vaccine within 28 days prior to first dose.\n\n          -  Been treated with a stimulator of interferon genes (STING) agonist (eg, MK-1454,\n             ADU-S100 [synthetic cyclic dinucleotide (CDN)]).\n\n          -  Has a history of re-irradiation for SCCHN at the projected injection site.\n\n          -  Has a tumor(s) in direct contact or encases a major blood vessel and has ulceration\n             and/or fungation onto the skin surface at the projected injection site.

Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment, except prophylactic antibiotics

Any patient receiving treatment with short-acting octreotide, which cannot be interrupted for 48 hours before and 24 hours after the administration of yttrium Y 90-edotreotide (90Y-DOTA-TOC), or any patient receiving treatment with octreotide LAR or lanreotide, which cannot be interrupted for at least 4 weeks before the administration of 90Y-DOTA-TOC\r\n* Concurrent somatostatin receptor analog (SSA) allowed if progression has been documented and the SSA dose has been stable for at least two months; long-acting SSA cannot be given within four weeks of treatment and short-acting SSA cannot be given with 48 hours of treatment; SSA therapy can restart one day after treatment

Participants with symptomatic hyperviscosity or serum IgM > 5,000 mg/dL to undergo plasmapheresis prior to treatment initiation

More than 1 prior VEGF-targeted treatment for advanced RCC

ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients planning to embark on a new strenuous exercise regimen after the first dose of study treatment

Patients currently receiving active treatment for melanoma

Active hepatitis C (HCV) infection without treatment is permitted; concomitant treatment of HCV is not permitted on this study

Is willing to undergo a mandatory pre-treatment research biopsy

Patients should have been off conventional therapy for at least 1 week prior to receiving treatment on this study

Prior treatment with enzalutamide for CPRC; non-CRPC use is allowed (e.g., neoadjuvant, combined with radiation for localized disease and didn’t progress while on it in those settings)

No prior systemic NSCLC treatment.

Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.

Patients on bisphosphonates may continue receiving bisphosphonate therapy during study treatment

Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment

Clinical trials prior to enrollment are allowed, as long as no brain directed therapy was included (current treatment trials are exclusionary)

Confirmation that the patient’s health insurance will pay for the treatment in this study (patients may still be responsible for some costs, such as co-pays and deductibles); if the patient’s insurance will not cover a specific treatment in this study and the patient still wants to participate, confirmation that the patient would be responsible for paying for any treatment received

Treatment with cytarabine at any dose, lenalidomide, or any other therapy targeted to the treatment of MDS (other than growth factors and other supportive care measures) within 4 weeks of planned randomization

Previous treatment with any HER2-targeted therapy Erlotinib

Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment

Prior treatment with cabozantinib (XL184)

Agreement to biopsies before and during treatment, depending on study part

Prior treatment with SGN-LIV1A or prior treatment with an MMAE-containing therapy

Patients receiving immunotherapy for non-cancer related treatment within < 4 weeks of first planned dose of study treatment will be excluded.

Women who are pregnant or breastfeeding. Women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with nab-paclitaxel and gemcitabine and for 180 days after the last dose of nab-paclitaxel and gemcitabine.

Any number of prior treatment regimens

No prior treatment with enzalutamide, ARN-509, ODM-201, galeterone or other investigational androgen receptor (AR) targeted treatment is allowed

Prior treatment with Provenge vaccine and 223 radium (Xofigo) is allowed if > 4 weeks from last dose

Patients on either treatment arm will considered for crossover if they demonstrate evidence of radiographic disease progression from the initial treatment

Prior treatment with enzalutamide is prohibited

Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ?100 mg per day, within the last 2 weeks

Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis. Previous treatment with itraconazole and fluconazole is permitted.

Prior treatment with enzalutamide or other potent androgen-receptor blockers, approved or experimental (e.g., ARN-509, ODM-201, or galeterone)

Prior treatment with flutamide (Eulexin®), steroidal anti-androgens (e.g., cyproterone acetate, chlormadinone acetate), androgens, or estrogens treatment within 4 weeks of Cycle 1, Day 1

Prior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks of Cycle 1, Day 1

Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment

Previous treatment with gemcitabine

Prior treatment with FR-targeting investigational agents is not allowed

Subject is receiving excluded therapy/treatment per protocol

Patient must be accessible for treatment and follow-up.

Presence of at least 1 non-target lesion suitable for multiple biopsies while on treatment.

Any cytotoxic chemotherapy, investigational agents, or anticancer drugs for advanced NSCLC used for a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.

Previous hysterectomy and/or prior treatment for cervical precancer condition

Treatment with cytotoxic or targeted antineoplastics within 3 weeks of initiation of study treatment. For cytotoxic agents that have major delayed toxicity a washout period of one cycle is indicated (examples are nitrosoureas and mitomycin C which typically require a 6 week washout). Prior antibodies or immunotherapies require a 6 week washout.

Prior treatment with anti?cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapeutic agents (e.g. ipilimumab)

Subjects must have received at least 1 and not more than 3 previous lines of treatment and have had a response to at least 1 prior Treatment in the past (i.e., achieved a minimal response [MR] or better) according to the IMWG uniform response criteria.

Prior treatment with radium-223 dichloride or any experimental radiopharmaceutical.

Participant has received or will receive some form of treatment for their cancer prior to completing a minimum of 14 days of study agent dosing; (a biopsy is not considered a form of treatment)

TREATMENT INCLUSION: Electrocardiography (EKG) shows no significant arrhythmias

Has demonstrated clinical benefit from treatment with tazemetostat.

Has been permanently discontinued from tazemetostat therapy due to adverse event, intolerance or treatment failure

Participants who have not recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to the study.

Current active treatment in another clinical study.

Patients may have had previous systemic treatment regimens (no limit to number of prior therapies); patients with prior treatment with bevacizumab are eligible for enrollment into the study; NOTE: except for bevacizumab, a 28 day wash-out period prior to registration is mandatory for all systemic treatments

No more than 3 prior lines of treatment for cGVHD.

Use of any vaccines against infectious diseases within 4 weeks of initiation of study treatment.

Prior treatment with at least 2 lines of therapy for HL including brentuximab vedotin; in those patients who cannot receive brentuximab vedotin, treatment with 2 prior therapeutic regimens is sufficient

Note: (supportive transfusions will be allowed during treatment as deemed necessary by the treating physician)

Ongoing treatment with an anticancer agent for CMML not contemplated in this protocol. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 7.

Prior treatment as follows:

Cytoreduction allowed with hydroxyurea and/or leukapheresis for up to 14 days prior to day (D)1 of treatment under LCCC1522; patients must be off hydroxyurea for >= 12 hours prior to D1 of treatment under LCCC1522

For patients that relapse following a response to prior treatment with bortezomib or carfilzomib, six months must have elapsed since the last dose of treatment

Peripheral blood lymphoblasts =< 50,000 mcL; hydroxyurea and/or leukapheresis is permitted to reduce the peripheral blast count prior to enrollment and treatment

Ongoing treatment with Coumadin.

Psoriasis or eczema not requiring systemic treatment.

Consent for on-treatment paired biopsies

Able to tolerate CPI treatment regimen {if already starte

Radiotherapy delivered to non-target lesions within one week prior to starting study treatment or delivered to target lesions that will be followed on the study (note: prior sites of radiation will be recorded).

Willingness to have pre treatment and on treatment tumor biopsies.

Hematologic growth factors are not allowed at Screening or during the first cycle of treatment

Histologically documented cluster of differentiation (CD) 20-positive B-cell lymphoma classified as relapsed or refractory FL or DLBCL after treatment with at least two prior chemoimmunotherapy regimens that included an anti-CD20 monoclonal antibody (mAb) and for which no other more appropriate treatment option exists

Inclusion criteria for all parts of the study\n\n          -  Confirmation of locally advanced/metastatic cancer. Refractory or resistant to\n             standard therapy, or have no effective standard\n\n          -  Aged at least 18 yrs\n\n          -  Reasonable health (performance status 0 or 1), stable over the previous 2 weeks\n\n          -  Females who can have children must use contraception; have a negative pregnancy test,\n             & not be breast feeding\n\n          -  Sexually active male patients must use contraception for duration of study and for 3\n             months afterwards Inclusion criteria for Part B only\n\n          -  Tumour(s) that can be measured by CT or MRI, at least 1cm in size Inclusion Part B\n\n          -  Confirmation of metastatic/locally advanced cancer of specific tumour type which\n             failed to respond to standard treatments Exclusion criteria for all parts of the study\n\n          -  Prior treatment with an ATM inhibitor\n\n          -  Past medical history of an inflammatory type(interstitial) lung disease or current\n             inflammatory lung disease\n\n          -  Radiotherapy within the last 4 weeks, except palliative radiotherapy for bone pain\n             relief\n\n          -  Prior treatment with drugs that may cause lung damage\n\n          -  Poor of lung function\n\n          -  History/presence of muscle weakness or abnormal blood tests relating to muscle\n             function\n\n          -  Cancer affecting the spinal cord and/or brain unless asymptomatic and stable\n\n          -  Any evidence of severe or uncontrolled diseases, active bleeding,kidney transplant, or\n             active infection including liver infections (hepatitis B, hepatitis C) and human\n             immunodeficiency virus (HIV).\n\n          -  Evidence of severe lung infections\n\n          -  Receiving, or having received during the four weeks prior to starting study treatment\n             other chemotherapy treatment for your cancer\n\n          -  Treatment with certain doses of steroids during the two weeks prior to starting study\n             treatment\n\n          -  A known sensitivity to AZD0156 or any of its components\n\n          -  Treatment with any unapproved medicine within 28 days prior to starting study\n             treatment\n\n          -  Receiving, or having received medications, herbal supplements and/or foods that\n             significantly affect how your liver works\n\n          -  Low numbers of certain blood cells\n\n          -  If your liver and kidney aren't working normally\n\n          -  If your heart isn't working normally or you have a strong family history of certain\n             heart diseases\n\n          -  Other cancers within the past 3 years, except for certain types of cervical and skin\n             cancers\n\n          -  Sickness and vomiting, digestive diseases or previous significant bowel removal\n\n          -  Patients with uncontrolled fitting\n\n          -  Infections requiring treatment\n\n          -  Other severe and/or uncontrolled medical conditions in addition to your cancer\n\n          -  A blockage in your digestive system or severe bleeding from the stomach within 4 weeks\n             before your take medication on the stuy\n\n          -  Patients with acute leukaemia or certain bone marrow diseases\n\n          -  Patients with a known sensitivity to olaparib or its components (Module 1), or\n             components of FOLFIRI (Module 2)\n\n          -  Any previous treatment with drugs that work like olaparib. (Module 1 Only)

Patients who are receiving any other investigational agents, with the exception of virus-specific cytotoxic T-cells for the treatment of viral infection/reactivation prior to allo BMT

Treatment with colchicine is excluded.

Prior treatment with lenalidomide; patients previously treated with thalidomide who discontinued treatment for reasons aside from an adverse reaction to thalidomide are permitted

Prior treatment with a monoclonal antibody or chimeric antigen receptor T cell infusion for the treatment of AML

Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.

Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study

Prior treatment with afatinib

Subjects are willing to undergo a biopsy to confirm lower GI aGVHD. Biopsy results are not needed to initiate treatment. However, if aGVHD is not confirmed histologically, treatment with F-652 will be discontinued.

Subjects, who have received previous systemic corticosteroids treatment or poorly absorbable corticosteroids for the treatment of aGVHD, for longer than 3 days (72 hours).

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study

Patients undergoing primary medical treatment (hormone or chemotherapy) as initial treatment with neoadjuvant intent of reducing tumor size

relevant toxicity from previous treatment

Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.

Active other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatment and would interfere with follow-up assessments through year 5

Must have fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy, surgery, or other anti-cancer modalities (returned to baseline status as noted before most recent treatment or =< grade 1)

All previous cancer therapy (with the exception of hydroxyurea) including donor lymphocyte infusions must have been discontinued at least 2 weeks prior to treatment in this study

Prior treatment with any anti-angiogenic agent (including bevacizumab)

Unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment

Patients may have received treatment of completely resected early stage melanoma, comprising interferon, radiation treatment, or experimental vaccine therapy, and in the metastatic setting patient can have had treatment such as chemotherapy, immunotherapy (except prior treatment with ipilimumab and IL-2), and other experimental agent which was completed 4 weeks prior to enrollment

Patients may be treatment-naive or have failed previous regimen of intravesical therapy

At least 3 weeks beyond the last chemotherapy, targeted anticancer agent, major surgery or experimental treatment and recovered from all acute toxicities (? Grade 1). Hydroxyurea used to control peripheral blast counts is permitted up to Day 7 of treatment on study.

Have been informed of other treatment options

Prior treatment with compounds with the same mode of action

Prior treatment with bevacizumab or other agents targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR)

Patient’s physician has already recommended enzalutamide for treatment of progression

Previous treatment with enzalutamide (MDV3100)

No systemic treatment in the previous 28 days.

Have taken any chemotherapeutic agent within 5 weeks of treatment with the NanoKnife irreversible electroporation (IRE) system

Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment

Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes

Patients who have had previous treatment with bevacizumab and/ or NovoTTF 100A system

Concomitant treatment with other anti-neoplastic agents, with the exception, when clinically indicated, of prophylaxis in the post-transplantation setting with intrathecal chemotherapy

History of changes in baseline LVEF that occurred during prior treatment with anti-HER2 treatment

For Cohorts 1, 3 and 4 only: Has received treatment with rituximab, alemtuzumab, ofatumumab or any other chemotherapeutic agent for CLL. Cohort 8: Received prior treatment with bendamustine and did not respond during treatment or relapsed less than sex months after completing treatment.

Concurrent systemic treatment or prior therapy within 4 weeks for SMM; NOTE: Treatment with corticosteroids for other indications is permitted

Patients who have not fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment). The required minimum time elapsed from prior treatments are:

treatment with molecular targeted agents within 2 weeks prior to treatment with APS001F.

Patients with previous treatment with abraxane

Patients should be > 24 hours from radiation therapy (RT) treatment to areas of the neuro-axis and all effects of treatment should have resolved

TREATMENT WITH SJCAR19: Known primary immunodeficiency

Hematologic growth factors are not allowed at screening or during the first cycle of treatment

Prior treatment with folate receptor (FR) targeting investigational agents is allowed for dose escalation provided that such treatment was not discontinued due to adverse events; prior FR-targeting investigational agents are not allowed for patients in the expansion cohort

Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities).

Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.

Diagnosis and Prior Treatment:

Prior history of treatment with blinatumomab

Prior treatment with a therapeutic agent targeting CD33 and/or CD3 (e.g. gemtuzumab ozogamicin, SGN-CD33A or AMG 330).

Treatment with systemic immunostimulatory agents;

Major surgery within prior 4 weeks of treatment initiation (the surgical incision should be fully healed prior to all neoadjuvant treatment initiation)

Prior enzalutamide and/or abiraterone treatment is allowed

Any prior PSA, MUC1, and/or brachyury-targeted immunotherapy (e.g., vaccine) must have been discontinued at least 12 weeks before initiation of study treatment; subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study

Prior treatment with adenovirus-based vectors immunotherapy

No prior treatment with temozolomide

Subject must have received no prior treatment for AML; hydroxyurea is not considered a treatment and is allowed

Prior treatment with ixazomib

Treatment failure of either abiraterone and/or enzalutamide as evidenced by a confirmed rising PSA (per PCWG3 criteria) and a castrate serum testosterone level (i.e. =< 50 mg/dL) while receiving treatment with either abiraterone and/or enzalutamide

Previous first line treatment with at least radiotherapy.

An interval of >= 4 weeks after the last administration of any other treatment for GBM.

WOCBP must use appropriate method(s) of contraception from the time of enrollment for the duration of treatment with study drug (s) plus 5 half-lives of study drug (s) plus 30 days (duration of ovulatory cycle) for a total of 23 weeks post treatment completion for subjects enrolled to treatment arm A (nivolumab). Subjects enrolled to treatment arm B (nivolumab + bevacizumab) must use appropriate method(s) of contraception for 6 months post treatment completion.

Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to randomization.

Previous bevacizumab or other vascular endothelial growth factor (VEGF) or anti-angiogenic treatment.

Prior treatment with ADI-PEG 20, gemcitabine, or docetaxel

Dose Expansion cohorts: Prior treatment with osimertinib (Tagrisso®). Prior treatment with osimertinib (Tagrisso®) is allowed for subjects participating in the dose escalation portion of the study

Cohort #1: received only frontline CD20-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy for patients with DLBCL; monotherapy rituximab or other CD20-directed immunotherapy prior to frontline chemotherapy, as maintenance therapy, and radiotherapy in a limited field or as a part of the frontline treatment plan are permitted; last treatment dose should be 3 weeks before start of study treatment

Prior systemic treatment of any kind or radiotherapy for RCC

Requires prohibited treatment (i.e., non-protocol specified anticancer pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant tumor). Limited field single dose radiotherapy for pain palliation would be allowed.

Cohort A: Patients must have progressed during treatment with abiraterone

Patients who are currently receiving treatment with contraindicated corrected QT interval (QTc) prolonging medications or potent CYP3A4 inducers, if that treatment cannot be either discontinued or switched to a different medication prior to first day of study treatment

Treatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megesterolacetate], or immunotherapy) =< 14 days prior to treatment with osimertinib

Patients must have had at least prior treatment with a fluoropyrimidine and either oxaliplatin or irinotecan.

Had prior treatment with Gliadel

Ability to comply with treatment, PK and test schedules

Prior treatment with CD74 targeting therapy

A medically appropriate candidate for ibrutinib treatment (based on the judgement of the clinical investigator).

Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs) (see Appendix B), during the treatment phase of the study and within 2 weeks prior to starting treatment. Concurrent dexamethasone is allowed.

Treatment with any of the drugs listed in Section 8.4.5 at the time of study treatment initiation.

Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)

Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment

Has an adequate treatment washout period prior to enrollment

Any prior treatment with azacitidine or decitabine

Have a documented advanced (metastatic and/or unresectable) gastroesophageal adenocarcinoma that is incurable and for which prior first-line or later-line standard of care (SOC) treatments have failed. There is no limit to the number of prior treatment regimens. Prior neoadjuvant or adjuvant therapy included in initial treatment may not be considered first- or later-line SOC treatment unless such treatments were completed less than 12 months prior to the current tumor recurrence.

Patients excluded with any prior treatment of pneumonitis requiring corticosteroids.

Subjects may have previously progressed on treatment with one of the 3 agents being used in this trial or treatment with other checkpoint inhibitors, as long as they have recovered from previous toxicity; subjects that previously progressed on treatment with a combination of any 2 of the 3 agents being used in this trial are eligible for the triplet cohort only

Must be agreeable to the mandatory research tumor biopsies (pre-treatment and on-treatment); tumor biopsies are mandatory at pre-treatment and at on-treatment; there is an optional biopsy at post-progression

Prior treatment with blinatumomab or CD-directed CAR T-cell therapy

Immunotherapy-naive and have either progressed on, are intolerant to, or refused treatment with sorafenib. Subjects who receive treatment with systemic therapies other than sorafenib are not eligible.

In stratum A, patients must have failed one prior systemic chemotherapy regimen; in stratum B, patients must have failed one prior systemic chemotherapy regimen, which must include cladribine/cytarabine or are not considered to be eligible for such treatment; in stratum C, Rosai Dorfman disease (RDD) patients must have failed treatment with corticosteroid; Erdheim Chester disease (ECD) patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatment

Need for systemic treatment with corticosteroids for cGVHD

No previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP])

Participants may be receiving other immunosuppressants for the prophylaxis or treatment of acute GVHD but if the subject is receiving prednisone for prophylaxis or treatment of acute GVHD it must be at or below 0.5 mg/kg/d

Prior treatment with NKTR-102.

Previous treatment with a pyrrolobenzodiazepine (PBD)-based drug Additional exclusion criteria for the SC-003 and ABBV-181 combination treatment regimen:

Extensive concurrent perianal or lower vulvar HSIL or condyloma requiring a different treatment modality than the study treatment, or treatment that cannot be deferred in observation arm, per examining provider

Treatment for anal or perianal HSIL, low-grade squamous intraepithelial lesion (LSIL) or condyloma within 4 months of randomization; please note that infrared coagulation (IRC) or electrocautery of a biopsy site to stop bleeding does not constitute treatment

Radiotherapy (except for brain and extremities or stereotactic treatment) within the past 2 weeks prior to treatment with the trial drug

Prior treatment with nintedanib (BIBF1120)

Prior Treatment\r\n* Patient must have failed at least one prior systemic therapy that included everolimus; disease progression or treatment intolerance leading to discontinuation is considered treatment failure\r\n* Prior treatment (except somatostatin analogs) with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, and/or radiation must be completed at least 28 days prior to registration\r\n* Prior treatment with somatostatin analogs is allowed, and continuation of treatment with somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months\r\n* Prior systemic treatment with radionuclide therapy must be completed at least 6 weeks prior to registration\r\n* Prior treatment with hepatic artery embolization (including bland embolization, chemoembolization, and selective internal radiation therapy) or ablative therapies is allowed if measurable disease remains outside of the treated area or if there is documented disease progression in a treated site; prior liver-directed or other ablative treatment must be completed at least 28 days prior to registration\r\n* Prior treatment with cabozantinib is not allowed\r\n* Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade 1 or less\r\n* Patients must have completed any major surgery at least 12 weeks prior to registration and any minor surgery (including uncomplicated tooth extractions) at least 28 days prior to registration; complete wound healing from major surgery must have occurred at least 28 days prior to registration, and complete wound healing from minor surgery must have occurred at least 10 days prior to registration

No prior treatment with an anthracycline and taxane

Other clinically significant disorders such as: i. active infection requiring systemic antibiotic treatment within 14 days before the first dose of study treatment ii. serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment iii. history of organ transplant iv. concurrent uncompensated hypothyroidism or thyroid dysfunction (thyroid-stimulating hormone [TSH] above 10) within 28 days before the first dose of study treatment v. major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.

Any prior treatment for NSCLC

Relapsed or refractory after at least one prior treatment regimen

No prior treatment with a hypomethylating agent, or previous exposure to DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401)

Actively participating in another clinical treatment trial

Any prior treatment for SCCHN

Patient has been previously permanently discontinued from study treatment in the parent protocol.

A WOCBP who agrees to follow the contraceptive guidance in protocol during the treatment period and for at least 120 days after the last dose of trial treatment.

Presence of at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by irRECIST

Participants may have received 0-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days prior to registration; participants should also be adequately recovered from acute toxicities of prior treatment

Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment

Unwillingness to accept the treatment;

Concomitant therapy that includes other chemotherapy that is or may be active against AML except for prophylaxis and/or treatment of opportunistic or other infection with antibiotics, antifungals and/or antiviral agents.

Resolution of treatment-related toxicities.

Inclusion Criteria:\n\n        For inclusion in this study, patients must fulfil the following criteria:\n\n          -  Has read and understands the informed consent form (ICF) and has given written\n             informed consent prior to any study procedures.\n\n          -  Female or male aged ?18 years.\n\n          -  Has completed 1 of the parent AZD1775 clinical pharmacology studies (ie, D6014C00002,\n             D6014C00003, D6014C00004, D6014C00005, or D6014C00006) and in the Investigator's\n             opinion will continue to benefit from treatment with AZD1775. Patients who discontinue\n             early from the parent study will be considered by the Sponsor and treating physician\n             on a case-by-case basis.\n\n          -  Any prior radiation must have been completed at least 7 days prior to the start of\n             study treatment, and patients must have recovered from any acute effects prior to the\n             start of study treatment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1.\n\n          -  Baseline laboratory values within 7 days of study treatment initiation in the CA\n             study:\n\n               -  Absolute neutrophil count (ANC) ?1500/?L.\n\n               -  Haemoglobin ?9 g/dL.\n\n               -  Platelets ?100,000/?L.\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 x upper\n                  limit of normal (ULN) or ?5 x ULN if known hepatic metastases.\n\n               -  Serum bilirubin within normal limits or ?1.5 x ULN in patients with liver\n                  metastases; or total bilirubin ?3.0 x ULN with direct bilirubin within normal\n                  limits in patients with well documented Gilbert's Syndrome.\n\n               -  Serum creatinine ?1.5 x ULN, or measured creatinine clearance (CrCl) calculated\n                  by Cockcroft-Gault method ?45 mL/min (confirmation of creatinine clearance is\n                  only required when creatinine is >1.5 x ULN) CrCl (glomerular filtration rate) =\n                  (140-age) x (weight/kg) x Fa (72 x serum creatinine mg/dL) where F = 0.85 for\n                  females and F = 1 for males.\n\n          -  Female patients who are of non-childbearing potential and fertile women of\n             childbearing potential (WoCBP) who agree to use adequate contraceptive measures that\n             are in place during screening (or consent), for the duration of the study, and for 1\n             month after treatment stops; who are not breastfeeding; and who have a negative serum\n             or urine pregnancy test prior to the start of study treatment.\n\n          -  Male patients must be willing to use barrier contraception (ie, condoms) for the\n             duration of the study and for 3 months after study treatment discontinuation.\n\n          -  Willingness and ability to comply with the study and the follow-up procedures.\n\n        Exclusion Criteria:\n\n        Patients must not enrol in this study if any of the following exclusion criteria are\n        fulfilled:\n\n          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca\n             personnel and/or personnel at the study centre).\n\n          -  Previous enrolment and received study treatment in the present study. Patients can,\n             however, be re-screened if the reason for the screen failure no longer exists.\n\n          -  Concurrent enrolment in another clinical study, unless it is an observational\n             (non-interventional) clinical study or the follow-up period of an interventional\n             study.\n\n          -  Must not have received another systemic anti-cancer therapy in the interval following\n             participation in the AZD1775 clinical pharmacology study and the start of treatment on\n             the CA protocol.\n\n          -  Not developed any clinical findings suggestive of brain metastasis. Patients continue\n             to be neurological stable and remain off systemic corticosteroids following treatment\n             of known brain metastases.\n\n          -  Did not tolerate AZD1775 in the parent study in the opinion of the Investigator.\n\n          -  Where a course of palliative radiotherapy was indicated, the last fraction must have\n             been delivered before the start of study treatment on the CA study.\n\n          -  Major surgical procedures ?28 days of beginning study treatment, or minor surgical\n             procedures ?7 days. No waiting period required following port-a-cath placement or\n             other central venous access placement.\n\n          -  Grade >1 toxicities from prior therapy, according to the Common Terminology Criteria\n             for Adverse Events (CTCAE), excluding alopecia or anorexia.\n\n          -  Continue to be able to swallow oral medication, did not undergo placement of a\n             percutaneous endoscopic gastrostomy tube and did not require total parenteral\n             nutrition.\n\n          -  Has had prescription or non-prescription drugs or other products known to be sensitive\n             to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be\n             moderate to strong inhibitors/inducers of CYP3A4 between the parent study and entry\n             into this CA study. Co administration of aprepitant or fosaprepitant during this study\n             is prohibited.\n\n          -  Has consumed herbal preparations between the parent study and entry into this CA\n             study.\n\n          -  Has consumed grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,\n             or other products containing grapefruit or Seville oranges between the parent study\n             and entry into the CA study.\n\n          -  Any known hypersensitivity or contraindication to AZD1775 or to the components\n             thereof.\n\n          -  Any of the following cardiac diseases currently or within the last 6 months as defined\n             by the New York Heart Association ?Class 2:\n\n               -  Unstable angina pectoris.\n\n               -  Congestive heart failure.\n\n               -  Acute myocardial infarction.\n\n               -  Conduction abnormality not controlled with pacemaker or medication.\n\n               -  Significant ventricular or supraventricular arrhythmias (patients with chronic\n                  rate-controlled atrial fibrillation in the absence of other cardiac abnormalities\n                  are eligible).\n\n          -  AZD1775 should not be given to patients who have a history of Torsades de pointes\n             unless all risk factors that contributed to Torsades have been corrected. AZD1775 has\n             not been studied in patients with ventricular arrhythmias or recent myocardial\n             infarction.\n\n          -  Patient with mean resting QTc interval (specifically QTc calculated using the\n             Fridericia formula [QTcF]) >450 ms for males and >470 ms for females from 3\n             electrocardiograms (ECGs) performed within 2 to 5 minutes apart during screening, or\n             congenital long QT syndrome.\n\n          -  Pregnant or lactating female patients.\n\n          -  Serious, symptomatic active infection at the time of study entry, or another serious\n             underlying medical condition that would impair the ability of the patient to receive\n             study treatment.\n\n          -  Active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

Inclusion Criteria:\n\n          -  Patient has histologically or cytologically proven advanced (unresectable) or\n             metastatic cancer as outlined below according to study part and disease type:\n\n          -  Part A: Patients with previously treated advanced or metastatic cancer. Patient may\n             have received no more than 4 lines of treatment for advanced or metastatic cancer.\n             Hormonal treatment will not be considered a prior line of treatment.\n\n          -  Part B: Patients with advanced or metastatic cancer for which treatment with\n             carboplatin-paclitaxel is considered appropriate therapy. Patient may have received no\n             more than 1 prior line of chemotherapy in the metastatic setting. Hormonal treatment\n             will not be considered a prior line of treatment.\n\n          -  Part C: Patients with previously treated advanced or metastatic cancer. Patient may\n             have received no more than 4 lines of treatment for advanced or metastatic cancer.\n             Hormonal treatment will not be considered a prior line of treatment.\n\n          -  Part D: Patients in whom carboplatin-paclitaxel and bevacizumab is considered\n             appropriate therapy. Patient may have received no more than 1 prior line of\n             chemotherapy in the metastatic setting. Hormonal treatment will not be considered a\n             prior line of treatment.\n\n          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n\n          -  Patient has adequate organ function\n\n          -  Female patient has a negative serum pregnancy test within 72 hours prior to taking\n             study treatment if of childbearing potential and agrees to abstain from activities\n             that could result in pregnancy from screening through 180 days after the last dose of\n             study treatment, or is of non-childbearing potential.\n\n          -  Male patient agrees to use an adequate method of contraception and not donate sperm\n             starting with the first dose of study treatment through 90 days after the last dose of\n             study treatment. Note: Abstinence is acceptable if this is the established and\n             preferred contraception for the patient.\n\n          -  Patient has measurable lesions by RECIST v1.1.\n\n        For Part A and C, in addition to the general inclusion criteria, patients must also meet\n        the following additional criterion to be considered eligible to participate in this study:\n\n          -  Patient is able to take oral medications.\n\n          -  For patients to be eligible for any parts of the study using niraparib 300 mg as a\n             starting dose, a screening actual body weight ? 77 kg and screening platelet count ?\n             150,000 u/L is necessary.\n\n        Exclusion Criteria:\n\n        (Patients will not be eligible for the study entry if any of the following criteria are\n        met)\n\n          -  Patient has known active central nervous system metastases, carcinomatous meningitis,\n             or both.\n\n          -  Patient has a known additional malignancy that progressed or required active treatment\n             within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous\n             cell carcinoma of the skin that has undergone potentially curative therapy, or in situ\n             cervical cancer.\n\n          -  Patient is considered a poor medical risk due to a serious, uncontrolled medical\n             disorder, nonmalignant systemic disease, or active infection that requires systemic\n             therapy.\n\n          -  Patient has a condition (such as transfusion-dependent anemia or thrombocytopenia),\n             therapy, or laboratory abnormality that might confound the study results or interfere\n             with the patient's participation\n\n          -  Patient is pregnant or expecting to conceive children within the projected duration of\n             the study, starting with the screening visit through 180 days after the last dose of\n             study treatment.\n\n        Note: No data are available regarding the presence of niraparib or its metabolites in human\n        milk, or on its effects on the breastfed infant or milk production. Because of the\n        potential for serious adverse reactions in breastfed infants from niraparib, female\n        patients should not breastfeed during treatment with niraparib and for 1 month after\n        receiving the final dose.\n\n          -  Patient has a known history of human immunodeficiency virus (type 1 or 2 antibodies).\n\n          -  Patient has known active hepatitis B or hepatitis C.\n\n          -  Patient has an active autoimmune disease that has required systemic treatment in the\n             past 2 years.\n\n          -  Patient has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2,\n             anti-CTLA-4 including ipilimumab), or any other antibody or drug specifically\n             targeting T-cell co-stimulation or checkpoint pathways.\n\n          -  Patient has undergone prior treatment with a known PARP inhibitor.\n\n          -  Known history or current diagnosis of MDS or AML.\n\n        For Parts C and D only, patients will not be eligible for study entry if the following\n        additional exclusion criterion is met:\n\n          -  Patient has clinically significant cardiovascular disease (e.g., significant cardiac\n             conduction abnormalities, uncontrolled hypertension, myocardial infarction, cardiac\n             arrhythmia or unstable angina, New York Heart Association Grade 2 or greater\n             congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or\n             greater peripheral vascular disease, and history of cerebrovascular accident [CVA])\n             within 6 months of enrollment.\n\n          -  Patient has a history of bowel obstruction, including subocclusive disease, related to\n             the underlying disease and history of abdominal fistula, gastrointestinal perforation,\n             or intra abdominal abscesses. Evidence of recto-sigmoid involvement by pelvic\n             examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.\n\n          -  Patient has proteinuria as demonstrated by urine protein: creatinine ratio ?1.0 at\n             screening or urine dipstick for proteinuria ?2 (patients discovered to have ?2\n             proteinuria on dipstick at baseline should undergo 24-hour urine collection and must\n             demonstrate <2 g of protein in 24 hours to be eligible).\n\n          -  Patient is at increased bleeding risk due to concurrent conditions (e.g., major\n             injuries or surgery within the past 28 days prior to start of study treatment, history\n             of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or\n             clinically significant hemorrhage within the past 3 months).\n\n          -  Patient has a known hypersensitivity to bevacizumab components or excipients

Prior treatment with TAS-102

Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs), during the treatment phase of the study and within 2 weeks prior to starting treatment

Prior treatment with cisplatin and/or gemcitabine

Active gout or inflammatory arthritis requiring treatment

Inclusion Criteria:-\n\n          -  Participants with histologically confirmed advanced ovarian cancer or triple negative\n             breast cancer who in the opinion of the Investigator are appropriate for this study\n\n          -  Measurable disease by RECIST criteria version 1.1 prior to study drug administration\n\n          -  Performance status of 0 or 1 on the eastern Cooperative Oncology Group (ECOG) scale\n\n          -  Life expectancy, in the opinion of the Investigator, of at least 3 months\n\n          -  Disease-free of active second/secondary or prior malignancies for => 2 years with the\n             exception of squamous cell carcinoma of the skin, or carcinoma in situ of the cervix\n             or breast\n\n          -  Willing to provide the protocol specified tumor biopsies\n\n          -  Acceptable hematologic status, liver and renal function\n\n          -  Participants who have received prior treatment with CD137 agonists or immune\n             checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1\n             therapeutic antibodies, may be enrolled, provided the following requirements are met:\n\n               -  Minimum of 5 months from the last dose of anti-PD-1, anti-CTLA-4, anti-PD- L1 or\n                  CD137 agonist treatment\n\n               -  No history of severe immune-related adverse effects from CD137 agonist,\n                  anti?CTLA-4, anti-PD-1 or anti-PD-L1 (NCI CTCAE Grade 3 and 4). Any toxicity\n                  related to the therapy must have resolved completely, no residual toxicity as\n                  assessed by NCI CTCAE (v4.03)\n\n          -  Agree to use protocol defined methods of contraception\n\n        Exclusion Criteria:\n\n          -  Participants with history of prior malignancy except solid tumor treated curatively\n             more than 3 years ago without evidence of recurrence\n\n          -  Asymptomatic or symptomatic, untreated, or actively progressing central nervous system\n             (CNS) metastases\n\n          -  History of leptomeningeal disease\n\n          -  Uncontrolled tumor-related pain\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures. Participants with indwelling catheters are allowed.\n\n          -  Uncontrolled or symptomatic hypercalcemia\n\n          -  New York Heart Association Class III or IV cardiac disease, pericarditis, myocardial\n             infarction within the past 6 months, unstable arrhythmia\n\n          -  Fredericia-corrected QT interval (QTcF) > 470 milli seconds (msec) (female) or > 450\n             msec (male), or history of congenital long QT syndrome. Any electrocardiogram (ECG)\n             abnormality, including pericarditis, which in the opinion of the Investigator would\n             preclude safe participation in the study.\n\n          -  Active, uncontrolled bacterial, viral, or fungal infections within 7 days of study\n             entry requiring systemic therapy\n\n          -  Known clinically important respiratory impairment\n\n          -  History of major organ transplant\n\n          -  History of an autologous or allogeneic bone marrow transplant\n\n          -  Serious non-malignant disease that could compromise protocol objectives in the opinion\n             of the Investigator and/or the Sponsor\n\n          -  Pregnant or nursing women\n\n          -  Any systemic anticancer therapy within 3 weeks prior to Cycle 1 Day 1\n\n          -  Any radiation treatment to metastatic site within <= 14 days of Cycle 1 Day 1\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days\n             prior to Cycle 1 Day 1 or anticipation of need for major surgical procedure during the\n             course of the study\n\n          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to\n             chimeric or humanized antibodies or fusion proteins\n\n          -  Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster\n             ovary cells or any component of the atezolizumab formulation\n\n          -  Active or history of autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced\n             pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic\n             organizing pneumonia), or evidence of active pneumonitis on screening chest computed\n             tomography (CT) scan. History of radiation pneumonitis in the radiation field\n             (fibrosis) is permitted\n\n          -  Positive test for Human immunodeficiency virus (HIV)\n\n          -  Active hepatitis B or hepatitis C\n\n          -  Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or\n             anticipation that such a live, attenuated vaccine will be required during the study\n\n          -  Treatment with investigational therapy within 28 days prior to initiation of study\n             treatment\n\n          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation\n             of study treatment\n\n          -  Consumption of agents which strongly inhibit CYP3A4 enzyme, within 7 days prior to the\n             first dose of study treatment and during the study\n\n          -  Consumption of agents which strongly induce CYP3A4 enzyme, within 14 days prior to the\n             first dose of study treatment and during the study\n\n          -  Treatment with systemic immuno-stimulatory agents within 4 weeks or five half-lives of\n             the drug (whichever is shorter) prior to the first dose of study treatment\n\n          -  Treatment with systemic corticosteroids or other systemic immunosuppressive\n             medications within 2 weeks prior to the first dose of study treatment, or, anticipated\n             requirement for systemic immunosuppressive medications during the trial\n\n          -  History of allergic reactions attributed to components of the formulated product(s)\n\n          -  Unwillingness or inability to comply with procedures required in this protocol

Within 10 days of treatment initiation: Hematological\r\n* It is anticipated that refractory AML patients will have low hematological counts including platelet count, hemoglobin, and absolute neutrophil count. Thus, hematologic parameters will not be used for enrollment and initiation of treatment

Bisphosphonate treatment within 7 days prior to initiating study treatment (while on study, bisphosphonates can be administered only once a month, between Days 18 to 21 of the 28-day treatment cycle)

Must have an absolute blast count (ABC) of < 15 K/ul in the peripheral blood prior to initiating study treatment, performed within 10 days of treatment initiation; use of hydroxyurea to control blast counts prior to initiating study treatment is acceptable

Previous treatment with CD19-targeted CAR T cells

At least one cutaneous lesion that is amenable to treatment with topical imiquimod

Has previous treatment for higher-risk myelodysplastic syndromes (HR MDS) or low-blast AML with chemotherapy or other antineoplastic agents including hypomethylating agent (HMAs) such as decitabine or azacitidine. Previous treatment is permitted with hydroxyurea and with lenalidomide, except that lenalidomide may not be given within 8 weeks before the first dose of study drug.

Treatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate]) =< 14 days prior to treatment

Prior treatment as follows:

In dose expansion, patients must be willing to undergo a pre-treatment biopsy, and four research PET imaging techniques (11C-Glutamine and 18F-FSPG), two pre-treatment and two after one cycle of treatment

Patients receiving anti-herpes medication (i.e., acyclovir, famciclovir, or valacyclovir) within 1 week prior to initiating HF10 treatment; patients may not require intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug other than intermittent topical use

The investigator must document that he/she believes the subject would not benefit from additional BCG treatment at the time of study entry

Subjects can be treatment naive or may have had two prior regimens for recurrent cancer. They must be naive to treatment with PD-1/L1 or CTLA-4 inhibitors.

Any prior treatment with pomalidomide. Subjects who have prior treatment with other immunomodulatory compounds (thalidomide, lenalidomide) ARE eligible if they meet all other eligibility criteria and did not have allergic reactions or other \significant toxicity\ per Investigator discretion associated with lenalidomide or thalidomide use.

Subjects unable or unwilling to have their first randomized treatment within three weeks of the post induction imaging and within five weeks of their last induction treatment

Known active infection requiring parenteral anti-infective treatment at the time of initiation of treatment

Inclusion Criteria:\n\n          1. Fully understand the study and voluntarily sign the informed consent form;\n\n          2. 18-75 years of age\n\n          3. Body weight ? 45kg\n\n          4. Histologically or cytologically documented, locally advanced or metastatic solid\n             malignancy (except squamous NSCLC) that has progressed on approved systemic therapy,\n             the last dose of prior systemic anti-cancer therapy must have been administered ? 4\n             weeks prior to initiation of study treatment, and for whom no effective therapy or\n             standard of care exists.\n\n          5. Have measurable disease per RECIST Version 1.1 (expansion phase only)\n\n          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          7. Expected survival of more than 12 weeks;\n\n          8. For female patients of childbearing potential and male patients with partners of\n             childbearing potential, agreement (by patient and partner) to use a highly effective\n             form(s) of contraception that results in a low failure rate ( < 1% per year) when used\n             consistently and correctly, and to continue its use for 90 days after the last dose of\n             fruquintinib.\n\n        Exclusion Criteria:\n\n        Patients will be excluded from the study, if any of the following criteria is met:\n\n          1. Absolute neutrophil count (ANC) < 1.5×109/L, platelet count < 100 ×109/L, or\n             hemoglobin < 90 g/L;\n\n          2. Serum total bilirubin > 1.5 times the upper limit of normal (ULN);\n\n          3. Alanine aminotransferase (ALT) aspartate aminotransferase (AST) > 1.5 ULN in patients\n             without hepatic metastases or ALT, AST > 3 ULN in patients with hepatic metastases;\n\n          4. Serum potassium, calcium, or magnesium levels out of the normal laboratory reference\n             range, and clinically significant in the investigator's judgment.\n\n          5. Serum creatinine clearance < 60 mL/min;\n\n          6. Urine dipstick for proteinuria > 2 +. Patients discovered to have ? 1 + proteinuria on\n             dipstick urinalysis at baseline should undergo a 24-hour urine collection and must\n             demonstrate ? 1 g of protein in 24 hours;\n\n          7. Uncontrolled hypertension, defined as: systolic blood pressure ? 140 mmHg and/or\n             diastolic blood pressure ? 90mmHg;\n\n          8. International Normalized Ratio (INR) > 2 or activated partial thromboplastin time\n             (aPTT) > 1.5 ULN, except if the patient is currently receiving or intending to receive\n             anti-coagulants for therapeutic purposes (prophylactic use is allowed).\n\n          9. Risk of, or active hemorrhage: history or presence of active gastric/duodenal ulcer or\n             ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, or any\n             other condition that could possibly result in gastrointestinal tract hemorrhage or\n             perforation;\n\n         10. History or presence of hemorrhage from any other site (e.g., hemoptysis or\n             hematemesis) within 2 months prior to screening\n\n         11. History of a thromboembolic event (including DVT, pulmonary embolism, stroke and/or\n             transient ischemic attack) within 12 months prior to screening;\n\n         12. Patients with squamous non-small-cell lung cancer (NSCLC);\n\n         13. Clinically significant cardiovascular disease, including but not limited to acute\n             myocardial infarction or coronary artery bypass surgery within 6 months prior to\n             enrollment, severe or unstable angina pectoris, New York Heart Association Class\n             III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left\n             ventricular ejection fraction (LVEF) < 50%;\n\n         14. Mean corrected QT interval using the Fredericia method (QTcF) > 480 msec or any\n             factors that increase the risk of QTc prolongation or risk of arrhythmic events such\n             as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or\n             unexplained sudden death under 40 years of age in a next of kin relative.\n\n         15. Concomitant medications with a known risk of causing QT prolongation and/or Torsades\n             de Pointes (See list in Appendix E; source list is continuously updated online at\n             www.qtdrugs.org ).\n\n         16. Systemic anti-neoplastic therapies within 4 weeks prior to the initiation of\n             investigational treatment, including chemotherapy, radical radiotherapy,\n             hormonotherapy, bio-therapy and immunotherapy;\n\n         17. Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the\n             initiation of study treatment;\n\n         18. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of\n             study treatment (3 weeks for St John's Wort). See Appendix F for a list of such\n             medications.\n\n         19. Surgery prior to enrollment within 28 days prior to the initiation of study treatment\n             or unhealed surgical incision;\n\n         20. Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1\n             (except for alopecia);\n\n         21. Known human immunodeficiency virus (HIV), hepatitis A, B or C infection except for\n             fully recovered Hepatitis A. Previous medical history of hepatitis B virus (HBV)\n             infection regardless of drug control, HBV DNA ?104 ×copy number or ?2000 IU/mL;\n\n         22. Known clinically significant history of liver disease, including hepatitis or\n             cirrhosis; current alcohol abuse.,\n\n         23. Evidence of ongoing or active infection requiring intravenous antibiotics;\n\n         24. Women who are pregnant or lactating;\n\n         25. Central nervous system (CNS) metastatic disease or prior cerebral metastasis;\n\n         26. Inability to take medication orally, dysphagia or an active gastric ulcer resulting\n             from previous surgery (e.g., gastric bypass) or a severe gastrointestinal disease, or\n             any other condition that investigators believe may affect absorption of the\n             investigational product;\n\n         27. Received investigational treatment in another clinical study within 4 weeks prior to\n             the initiation of investigational treatment;\n\n         28. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory\n             result, or any other condition that investigators suspect may prohibit use of the\n             investigational product, affect interpretation of study results, or put the patient at\n             undue risk of harm.

Any number of prior treatments allowed for patients under 65 years (y), over 65y must have at least one prior line of TKI treatment (excluding anaplastic patients).

No prior virotherapy allowed

Documented disease progression or intolerance to treatment either during or after treatment with most recent therapy

A new diagnosis of de novo, secondary or treatment-related AML

Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval if that treatment cannot be either discontinued or switched to a different medication (not known to affect QT interval) prior to cycle 1 day 1 (C1D1)

Patients must consent to pre and on treatment research biopsies

Presence of at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by RECIST 1.1

Subjects with prior anti-PD-1, anti-PD-L1 treatment. For Arms A and D, subjects may not have had prior 4-1BB treatment. For Arms B and E, subjects may not have had prior OX40 treatment. For Arms C and F, subjects may not have had prior 4-1BB or OX40 treatment.

Prior treatment with cabozantinib or erlotinib

Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment

Willing to have peripheral blood mononuclear cells and bone marrow biopsies to be collected prior to receiving the first dose of durvalumab and tremelimumab, after 2-doses and 4-doses of durvalumab and tremelimumab, after 2nd treatment administration and 4th treatment administration.

Previous treatment with investigational gene or chimeric antigen receptor therapy;

Prior yttrium-90 radioembolization treatment

Patient willingness and disease accessible to pre-treatment, on-treatment tumor, and progression biopsies (core biopsies); a cell block from a pleural effusion may be substituted for a core biopsy; in select cases, patients may be allowed to enroll without a pre-treatment biopsy and/or continue treatment without an on-treatment biopsy (even if a pre-treatment biopsy is obtained) after speaking with the sponsor if performing the biopsy is technically challenging, poses significant risk to the patient, or may result in significant discomfort

Prior treatment with pazopanib

Availability of curative treatment option for the patient’s cancer, whether surgery, chemotherapy, radiation, or combination thereof, unless the patient has documented refusal of curative treatment

Previous treatment with investigational gene or chimeric antigen receptor therapy.

prior treatment as follows:

Prior treatment with murine and hu3F8 is allowed

Prior treatment with irinotecan or temozolomide is permitted

Previous treatment with any radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide used for labeling the respective radiopharmaceutical prior to the administration of study drug.

Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.

Prior treatment with carotuximab (TRC105)

Current treatment on another therapeutic clinical trial

History of peptic ulcer within the past 3 months prior to study treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days prior to study treatment

Patients who were enrolled into any other treatment clinical trial and received treatment on that trial within 4 weeks of study treatment

Prior treatment with nab-paclitaxel (abraxane)

Inclusion Criteria\n\n          1. Histologic confirmation of metastatic NSCLC. For subjects with EGFR mutations, prior\n             therapy must have included an EGFR tyrosine kinase inhibitor. Subjects must not have\n             ALK rearrangement.\n\n          2. Availability of archival (diagnostic) specimens or willing to undergo a pre-treatment\n             biopsy.\n\n          3. Subjects with treated brain metastases must have been treated with surgery and/or\n             radiation therapy ? 21 days pre-study and must be clinically stable with no\n             requirement for steroids.\n\n          4. Laboratory parameters for vital functions should be in the normal range.\n\n          5. ECOG Performance Status ? 2.\n\n        Exclusion Criteria\n\n        Subjects may not enter the study if they fulfill any of the following criteria:\n\n          1. Treatment with an investigational agent within 4 weeks of starting treatment or prior\n             treatment with a checkpoint inhibitor (CTLA-4, PD-1 or PD-L1 antibodies).\n\n          2. Active, suspected or prior documented autoimmune disease, clinically significant\n             cardiovascular disease, or clinically uncontrolled hypertension.\n\n          3. History of pneumonitis or interstitial lung disease, or any unresolved immune-related\n             adverse events following prior therapy.\n\n          4. Major surgery within 4 weeks of starting treatment (or scheduled for surgery during\n             the projected course of the study) or prior cancer vaccine treatment or allogeneic\n             bone marrow transplantation.\n\n          5. Subjects who are immunosuppressed, including those with known immunodeficiency or have\n             active infection including tuberculosis or other serious illnesses.\n\n          6. Skin disease (e.g., psoriasis) that may prevent intradermal administration of the\n             vaccine into the target areas.

Have participated in a prior oregovomab clinical trial. Prior treatment with Hiltonol® does not exclude a subject from participation.

At least two sites of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; one of which must be amenable to treatment with SAR and accessible for a mandatory pre-treatment biopsy and a post-treatment biopsy at physician discretion; if a pulmonary nodule is being considered for SAR it must range in size from 1-5 cm

Has had prior treatment with pembrolizumab

Has had prior treatment with cabozantinib

Prior treatment with immune checkpoint inhibitors is allowed, provided that no treatment-related grade >= 3 adverse events (other than grade 3 endocrinopathy managed with replacement therapy) were observed and at least a minimum of 28 days have elapsed between the last dose of prior treatment and the proposed cycle 1 day 1

Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC.

Adult subjects with advanced MDS requiring treatment with HMA and either refractory to at least 4 cycles or progressing after previously documented response\r\n* Patient must be treated within 6 months of the last HMA treatment and must be willing to be treated with the same agent they last received on this study\r\n* Prior treatment with novel HMA analog of decitabine on clinical trial is allowed; in such cases, decitabine will be used as the standard of care agent

FOCBP and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment period

Prior treatment with any therapy that is targeted to B cell maturation antigen (BCMA) or any other CD3-redirecting drug

No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigator’s opinion

Subjects must not have implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigator’s opinion

No endoluminal stent in place at the time of treatment

Subject is receiving excluded therapy/treatment per protocol

Prior treatment with palbociclib

FOR ALL PHASES (Ib AND II): Concurrent treatment with postmenopausal hormone replacement therapy; prior treatment must be stopped for at least 28 days prior to first baseline biopsy

No restrictions on prior treatment to be eligible

Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational medicinal product (IMP) within ? 5 x the half-life of the IMP prior to day 1 cycle 1 of Minnelide.

Ability to cooperate with study treatment and follow-up.

Patients with prior known toxicity from IL-17A directed therapy, which led to discontinuation of the study treatment, will be excluded from CJM112 containing arms of the study.

Appropriate for treatment with sunitinib in the opinion of the treating physician

Subjects must have received intravesical treatment with at least two doses of BCG within six months of nivolumab treatment initiation

CRITERIA FOR SCREENING: For patients in stage 1 only, prior treatment with any CD19 CAR T-cell therapy is excluded

Willing to refrain from using other lotions, creams, etc. during the treatment period;

Abstinence from all manner of physical contact near the treatment area during and up to 2 weeks after the treatment phase.

Elective surgery for treatment of the cutaneous metastases during the study and up to 4 weeks after the treatment period. Cutaneous metastases are required to remain in-situ and measurable for up to 2 weeks after last treatment to achieve study objectives;

Participation in the treatment phase of another clinical trial within the four weeks prior to treatment in this clinical trial;

No prior treatment with ONC201

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study

Histologically documented differentiated thyroid cancer with or without metastases, not amenable to curative treatment; or the patient has documented refusal of curative treatment

Ability to comprehend the nature of the treatment

Prior treatment with axitinib

Previous treatment with talimogene laherparepvec or any other oncolytic virus

Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec

At time of day 1 of protocol treatment, subjects with central nervous system metastases must have been treated and must be asymptomatic and meet the following:\r\n* No concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids\r\n* Neurologic stability (lack of signs and symptoms greater than baseline prior to x-ray therapy [XRT]) until the time of dosing\r\n* For radiation treatment, patients must not receive stereotactic radiosurgery or gamma knife treatment within 7 days of day 1 of protocol treatment; for whole brain radiotherapy (WBRT), there should be at least 28 days between last day of WBRT and day 1 of protocol treatment\r\n* Note: patients with leptomeningeal disease or cord compression are excluded from the study

Any previous treatment with a hypomethylating agent, including decitabine, azacitidine, or SGI-110

Prolonged antibiotic treatment (>= 10 days, within 3 weeks of enrollment) as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing anti anaerobic antibiotics

Treated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least 6 months post implantation

Prior treatment with trabectedin

Patients with previous history of vandetanib or cabozantinib treatment for more than 28 days of treatment (patients have discontinued treatment for 28 days before enrolling)

Prior treatment with gene modified T cells

Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec

Participant has received any prior treatment for AML with the exception of hydroxyurea, allowed through the first cycle of study treatment. Note: Prior treatment for Myelodysplastic Syndrome is allowed except for use of cytarabine.

Have received or are receiving an investigational medicinal product (IMP) or other systemic anticancer treatment within 2 weeks prior to the first dose of study treatment

Not suitable for SBRT treatment

Prior treatment with either decitabine or azacitidine

Patients may not have had prior radiotherapy (> 30 Gy) to the area requiring treatment that would result in any overlap of tissue in both fields

Patient who has had prior treatment with mistletoe

Patient who has had any prior radiotherapy to the treatment site(s)

Prior ALT-803

Prior treatment with either venetoclax or ibrutinib

Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 4 weeks prior to first administration of study treatment

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter the study

COHORT 1 (WITH SORFENIB): No previous systemic therapy including sorafenib or chemotherapy treatment; previous TACE and local treatments are permitted

Alemtuzumab treatment within 8 weeks of HSCT admission

Patients who are simultaneously enrolled in any other treatment study

PRE-SCREENING: No prior treatment with anetumab ravtansine (or any other mesothelin-based therapy)

Previous assignment to treatment during this study; patients permanently withdrawn from study participation will not be allowed to re-enter the study

Patients must not have had prior treatment of glioblastoma with stereotactic radiosurgery, brachytherapy, or carmustine-impregnated wafers (Gliadel).

Patients may not have undergone previous treatment with lomustine.

Has significant toxicities from prior treatment that have not resolved or stabilized

Prior treatment with cytotoxic drugs within 5 years of screening for any condition (example [e.g.], cancer, rheumatoid arthritis) or prior use of any anti-CD20 antibody

Per investigator's judgment, be eligible for treatment with valganciclovir.

Be receiving leflunomide, or artesunate when study treatment is initiated. Note: Subjects who may be receiving leflunomide must discontinue the use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment. Subjects receiving artesunate must discontinue the use prior to the first dose of study treatment.

Be on treatment with anti-CMV agents (ganciclovir, valganciclovir, foscarnet or cidofovir) for the current CMV infection for longer than 72 hours. Note: A subject who is receiving these anti-CMV agents must discontinue their use before the first dose of study treatment. A subjects who may be receiving cidofovir must discontinue this antiviral at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment. Note: Subjects who were administered these anti-CMV agents for prophylaxis, should have these treatments completed at least 2 weeks prior to the study entry or start of the treatment for current infection, whichever comes first and have undetectable CMV DNA (based on local laboratory) for at least two weeks between the completion of this treatment and onset of the current infection.

Prior treatment with all-trans retinoic acid (ATRA) or systemic retinoid for the treatment of hematologic malignancy.

Patients may concurrently receive bisphosphonates or rank ligand inhibitors while on this study if necessary for treatment or prevention of osteopenia or osteoporosis; prior treatment with LHRH agonists is allowed for premenopausal women; topical vaginal estrogen therapy is allowable

Tumor recurrence after previous treatment, which must have included at least radiation therapy and one cytotoxic chemotherapy; there is no limit on number of previous recurrences or lines of treatment

Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JCAR017 treatment in this protocol for subjects receiving retreatment

Treatment plan that includes post-transplant maintenance therapy

Prior treatment with any pan-HER TKI (eg, lapatinib, afatinib, dacomitinib, neratinib).

Unwilling or unable to discontinue disallowed disease-modifying antirheumatic drugs (DMARDs) for treatment of SSc prior to mobilization

Patients should be excluded if they have had prior treatment with cabozantinib; previous use of other antiangiogenic agents other than cabozantinib is allowed

Prior treatment with DCC-2618

Eligible to receive treatment with a CPI.

Prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).

Signs and symptoms of infection within 2 weeks of first study treatment; receipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment; subjects receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligible

Prior treatment with any LAG-3 targeting biologic or small molecule

Prior treatment with idelalisib

Previous treatment with any weekly taxane regimen.

No prior treatment with carmustine wafers

Have been informed of other treatment options

Prior treatment with fosbretabulin is allowed, if not given in combination with everolimus

Previously untreated for myeloma or have received no more than one cycle of any treatment regimen; NOTE: Prior radiation therapy for the treatment of solitary plasmacytoma is permitted; prior therapy with clarithromycin, dehydroepiandrosterone (DHEA), anakinra, pamidronate or zoledronic acid is permitted; any additional agents not listed must be approved by the principal investigator

The use of hydroxyurea before enrollment is permitted; hydroxyurea should be discontinued prior to start of study treatment; patients with symptoms/signs of hyperleukocytosis or white blood cell count (WBC) >100,000/uL can be treated with leukapheresis or may receive up to 1 dose of cytarabine (up to 500 mg/m^2) anytime prior to enrollment

The following patients are allowed:\r\n* Patients may have been treated for AML or antecedent hematologic disorder with myeloid growth factors, recombinant erythropoietin, thalidomide, lenalidomide, 5-azacitidine or decitabine\r\n* Any prior chemo therapy must have been completed >= 2 weeks prior to day 1 of study treatment and the participant must have recovered to eligibility levels from prior toxicity\r\n* There is no limit for prior chemo regimens\r\n* Patients may have received hematopoietic stem cell transplantation for AML or other diseases\r\n* Hydroxyurea is allowed prior to day 1 of study treatment for count control and during cycle 1; the use of hydroxyurea is not allowed beyond completion of cycle 1

Prior treatment with lenvatinib

Active treatment for VTE

Any prior systemic anti-cancer immunotherapy treatment

Signed and dated PICF obtained prior to initiation of any study-specific procedure and treatment.

Prior treatment or preventative use of any hormonal agent such as aromatase inhibitors (AI), fulvestrant, raloxifene, tamoxifen or other SERM, or with any other hormonal agent used for the treatment or prevention of BC or for any other indication (e.g. osteoporosis).

Prior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer.

Prior systemic treatment must be completed at least 14 calendar days prior to registration and the subject must have recovered from the toxicities of treatment to grade 1 or better

Previous treatment information (name of agent, treatment starting date, and date of progression) must be available for review

Unavailable for follow-up visits after treatment

Dose expansion - KRAS mutant patients groups: Prior treatment with a RAFi (including any BRAFi and pan-RAFi), MEKi and/or ERKi. BRAF mutant patients group: Prior treatment with an ERKi and/or a pan-RAFi.

At enrollment, patients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug

Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy\r\n* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids and/or lenalidomide and/or bortezomib/principal investigator (PI)-based regimens does not disqualify the subject (the corticosteroid treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle of lenalidomide and/or PI-based therapy)

Be willing to undergo normal skin biopsy prior to initiation of treatment and after treatment

Cardiac testing with either exercise stress test or thallium stress test, within 3 months of start of the first treatment day; atrial fibrillation that is rate controlled is allowed; note – the first treatment day is about 9 weeks before the first IL-2 treatment day; if a cardiologist’s evaluation determines that this is superfluous based on other assessments, then this may be omitted

Prior decitabine for the treatment of this cancer; patients with previous exposure to therapy with gemcitabine are allowed in the study

Leptomeningeal involvement regardless of treatment status

Patients who have the following risk factors are considered to be at increased risk for cardiac toxicities and may be enrolled only with increased monitoring: i) prior treatment with anthracyclines; ii) prior treatment with trastuzumab; iii) a New York Heart Association classification of II controlled with treatment; iv) prior central thoracic radiation therapy (RT), including RT to the heart

Must be treated per protocol to lesion(s) of a single abdominal site that can reasonably be encompassed within a single treatment field; treatment of additional site(s) outside of the abdomen while the patient is on trial is acceptable

Patients may not be receiving the treatment targeting the activated gene as part of a clinical treatment trial other than the Precision Oncology Trial

Leptomeningeal involvement regardless of treatment status

Have documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenib; intolerance to sorafenib is defined as: Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 drug-related adverse event(s) which both a) persisted in spite of comprehensive supportive therapy according to institutional standards and b) persisted or recurred after sorafenib treatment interruption of at least 7 days and dose reduction by one dose level; patients treated on sorafenib as the last treatment may start pembrolizumab at least 14 days after the last dose of sorafenib

Patient has received enzalutamide for the treatment of prostate cancer; however, previous treatment with other hormonal therapy (bicalutamide, abiraterone, ketoconazole, flutamide, and nilutamide) or chemotherapy (docetaxel, cabazitaxel, or mitoxantrone) is allowed

Subjects must have failed hypomethylating treatment where \failure\ is defined as: Progression (according to 2006 International Working Group [IWG] criteria) at any time after initiation of the hypomethylating treatment OR Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least 4 cycles treatment OR Relapse after initial complete or partial response or HI (according to 2006 IWG criteria).

Prior treatment with temozolomide, dacarbazine or procarbazine

Current treatment with agents that may prolong QT interval and may cause Torsade de Points which cannot be discontinued at least five half-lives prior to treatment

Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index

Treatment within 14 days prior to first study treatment with conventional therapy or treatment within 28 days prior to first study treatment with an investigational drug

Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within 2 weeks prior to starting treatment

FOCBP and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment period

Patient is currently receiving clinical benefit from the treatment with IMCgp100, as determined by the principal investigator from the parent study

Has prior treatment using an anthracycline

A blood pressure (BP) =< the 95th percentile for age, height and gender despite optimal antihypertensive treatment within 7 days of the first dose of the study treatment; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP

Have been informed of other treatment options and is not a candidate for standard treatment options or stem cell transplant at the time of enrollment

Prior DNA methyl transferase inhibitor administration (azacitidine, decitabine or guadecitabine) for AML or for antecedent MDS is allowed if this clinical trial is considered the best treatment option, but azacitidine, decitabine or guadecitabine must have been stopped at least 3 weeks prior to day 1 of treatment on the study

Participants are required to stop receiving myeloid growth factors at least 1 week (Neupogen) or 2 weeks (Neulasta) before starting treatment on the study

Hyperleukocytosis with > 50,000 blasts/ul; hydroxyurea for blast count control is permitted before starting treatment, but must be stopped prior to starting treatment on the study; patients will be withdrawn from the study if > 50,000 blasts/ul occur or recur > 14 days after starting treatment on the study

Previous treatment with talazoparib

Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog).

Patients having received prior radiotherapy, treatment with cytotoxic agents, treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy within the 4 weeks prior to treatment with selinexor, or those who have not fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)

Previous brentuximab treatment

Patients not previously treated for their FL, including any previous treatment for FL under clinical trials except localized radiation therapy for previous limited stage disease.

Patient has received niclosamide, abiraterone or ketoconazole for the treatment of prostate cancer; however, previous treatment with other hormonal therapy (bicalutamide, enzalutamide, flutamide and nilutamide) or chemotherapy (docetaxel, cabazitaxel or mitoxantrone) is allowed

Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted; prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is > 3 years

Treatment with radiation therapy within 12 weeks prior to the first dose of study treatment, unless there is tissue confirmation of tumor recurrence or there is progression outside the treatment field

Prior treatment with intracystic P-32 or intracystic bleomycin

Patients must have newly diagnosed AML or ALL without previous treatment; hydroxyurea will be allowed to control peripheral blast count as clinically indicated but would need to be stopped prior to initiation of tyrosine kinase inhibitor [TKI]); all-trans retinoic acid (ATRA) is permitted during the period prior to ruling out a diagnosis of APL; previous radiation treatment is allowable; patients must be deemed eligible for treatment with cytotoxic induction chemotherapy with cytarabine and idarubicin for AML or hyper-cyclophosphamide, dexamethasone, doxorubicin, vincristine sulfate (CVAD) for ALL; patients newly diagnosed with ALL must have received no prior treatment for their ALL with the exception of steroids (i.e. prednisone, dexamethasone); intrathecal methotrexate or cytarabine, allowed prior to and throughout the enrollment period for AML and ALL

Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)

Documented infections or oral temperature > 38.2 degree Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance therapy; however, if these problems resolve, the start of treatment can be initiated on a delayed schedule

Have received treatment with any form of therapy with CYP17 inhibitory activity such as ketoconazole, aminoglutethimide, or an antiandrogen such as bicalutamide within 6 months of study treatment initiation

mCRPC EXPANSION COHORT: Patients must have received prior treatment with enzalutamide and/or abiraterone with the exception of patients who were treated with docetaxel and androgen deprivation therapy for metastatic castrate-sensitive prostate cancer and progressed on docetaxel treatment or who progress within one month of the last docetaxel dose

mCRPC EXPANSION COHORT: The patient has received radionuclide treatment within 6 weeks prior to the first dose of the study treatment

If a curative treatment option in the form of chemoradiation exists in a patient with unresectable disease, this has to be attempted first and must have failed, unless the patient has documented refusal of curative treatment

Availability of curative treatment option for the patient’s cancer, whether surgery, chemotherapy, radiation, or combination thereof, unless the patient has documented refusal of curative treatment

If a subject is currently receiving bisphosphonates, the subject must have received the bisphosphonates for at least four weeks prior to the first dose of ARQ 751. a. Initiation of bisphosphonates during the study may be allowed provided the subject completes the first cycle of treatment without any dose limiting toxicity (DLT) and the Investigator rules out tumor progression.

Prior treatment with venetoclax or ibrutinib

Received prior treatment or receiving current treatment for this malignancy

If the patient has been using the Optune™ device, it will be discontinued before initiating treatment with either study medication, and per inclusion criterion listed above, the patient must have recovered from all treatment-related toxicities to Grade 1 or less.

Patients must be >= 14 days from previous cytotoxic treatment

Prior treatment with any CD19 CAR T-cell therapy

Any prior treatment with: ipilimumab

PRIOR TO LYMPHODEPLETION: Available autologous T cells with ? 15% expression of CD30CAR determined by flow cytometry required prior to treatment with ATLCAR.CD30 cells

Treatment plan that includes regional nodal irradiation

Unstable ventricular arrhythmia requiring treatment

There is no limit on the number of prior treatment regimens

Use of any active treatment for relapse/refractory AML including but not restricted to chemotherapy, targeted agents, hypomethylating agents or investigational drugs; use of hydroxyurea up to 6g per day for cytoreduction is allowed for a maximum of 15 days prior treatment

Patient is a candidate for, and agrees to proceed with additional bevacizumab treatment.

In first or subsequent relapse, or refractory to the last treatment (defined as less than a complete metabolic response to the last treatment, or within 6 months from the last treatment).

Treatment with plasmapheresis within 4 weeks prior to event 1

Current or previous treatment with investigational therapy in another therapeutic clinical trial interrupted less than 4 weeks before study treatment initiation.

Have been informed of other treatment options

Prior treatment with murine and hu3F8 is allowed; patients with prior humanizing murine IgG3 anti-GD2 antibody m3F8 (m3F8), hu3F8, ch14.18 or hu14.18 treatment must have human anti-human antibody (HAHA) antibody titer < 1300 enzyme-linked immunosorbent assay (ELISA) units/ml; human anti-mouse antibody positivity is allowed

Patients must not be pregnant at the time of SRS treatment

Prior radiotherapy that precludes the proposed treatment with hypofractionated radiotherapy

Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the study drugs; if such drugs have been used, patients must have discontinued these agents at least 2 weeks (or as noted below) prior to initiating study treatment; examples include:\r\n* STRONG CYP3A4 inducers \r\n* Immunosuppressants (e.g., tacrolimus, leflunomide, tofacitinib, roflumilast, pimecrolimus)\r\n* NSAIDs\r\n** Note: NSAIDs must be discontinued within 5 days prior to initiating study treatment

Patients must require systemic treatment

Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatment

Scheduled to undergo radioembolization for treatment of intrahepatic metastases

This study permits the re-enrollment of a patient who has discontinued the study for a reason other than treatment failure or adverse event(s) of the study treatment; the patient must be re-consented and assigned a new subject number

Current active treatment in another clinical study

Prior therapy with abiraterone, enzalutamide and/or docetaxel; there is no limit to the number of prior treatment regimens

Previous therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than 3 months ago \r\n* Note: previous myeloablative autologous transplant is permitted but not required

Male who is expecting to father a child during the treatment period

CAPMATINIB INCLUSION CRITERIA: Prior treatment with at least one Food and Drug Administration (FDA)-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician

CERITINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician

REGORAFENIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician

ENTRECTINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician

Prior treatment with anthracyclines

No prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatment

Patient received investigational treatment within 2 weeks or immunotherapy or antibody therapy within 28 days prior to initiation of treatment with Toca 511, and/or has not recovered from toxicities associated with such treatment.

Scheduled to undergo either partial or radical nephrectomy as part of treatment plan

No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator’s opinion

Participants must have received at least one but no more than six prior treatment regimens. Prior treatment with an anti-CD20 agent, either alone or in combination, is allowed.

Either: \r\n* Relapsed after or refractory to prior treatment with at least two regimens or lines of treatment\r\n* Prior failure of at least one regimen or line of treatment, with poor cytogenetic or other risk factors, and ineligible for other clinical trials

No more than 2 prior induction regimens (excluding prior HSCT) in their first line treatment and one must have included cytarabine with an anthracycline (or anthracenedione)

Prior treatment with an Murine Double Minute 2 (MDM2) antagonist

No more than 3 prior progressions

COHORT II: Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment)

Willingness to provide a fresh biopsy prior to study enrollment and after 2 cycles of treatment as clinically appropriate per PI discretion

Refractory to or relapsed after at least 1 prior treatment regimen

Must consent to study-specific biopsies at two separate timepoints: pre-treatment (Screening) and post-treatment (Day 28 or EOS).

For hypomethylating failure cohorts, treatment for MDS with any other drug not being an HMA with the following exceptions: prior treatment with growth factors and/or lenalidomide is allowed for any cohort

Prior treatment with carfilzomib

Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes

Patients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study:

Prior treatment with cabozantinib

No prior systemic treatment for acute GVHD except for a maximum of 3 days of prednisone (or IV methylprednisolone) ? 2 mg/kg/day; topical skin steroid treatment, non-absorbable oral steroid treatment for gastrointestinal (GI) GVHD, and resumption of GVHD prophylaxis agents (e.g., calcineurin inhibitors) are permissible; patients enrolled in BMT CTN 1501 who randomized to sirolimus are also eligible

Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria

Have a history of intolerance, hypersensitivity, or treatment discontinuation due to severe immune adverse events on prior immunotherapy, or documented presence of neutralizing anti-drug antibody to nivolumab, ipilimumab, or pembrolizumab. Subjects who discontinued prior immunotherapies for immune-related adverse events that are well-controlled with appropriate treatment may be enrolled if approved by the Medical Monitor.

Have current second malignancy at other sites, which requires treatment, or in the judgement of the Investigator, may require treatment within the next year. Concurrent malignancies that do not require treatment and are clinically stable are allowed. A past history of other malignancies is allowed as long as the subject is not receiving specific treatment other than hormonal therapy, and, in the judgement of the Investigator, is unlikely to have a recurrence.

Must meet one or more of the consensus criteria for initiating treatment MM Participants:

Must have undergone prior treatment with ?2 treatment lines of anti-myeloma therapy and failed last line of treatment (disease progression ?60 days of completion of last therapy)

Prior treatment with an anti-ErbB3 antibody

Previous treatment with farletuzumab or other folate receptor targeting agents

For subjects being enrolled to receive PLD plus carboplatin, prior treatment with anthracyclines or anthracenodiones

There is no limit to the number of prior treatment regimens provided that performance status and life expectancy meet the criteria above

All participants will be required to undergo mandatory pre and on-treatment biopsies

Subjects must not: have active herpetic skin lesions or prior complications of herpetic infection (eg, herpetic keratitis or encephalitis); require treatment with an antiherpetic drug; have received live-virus vaccination within 30 days of planned treatment start; have previous therapy with talimogene laherparepvec, oncolyic viruses, or tumor vaccine.

Prior treatment with leflunomide

Current or planned growth factor or transfusion support until after initiation of treatment; if growth factor or transfusion support is provided between screening and start of treatment, the participant will no longer be eligible

Prior treatment with other anti-GD2 antibodies is allowed (prior treatment with hu3F8 is NOT allowed), but human anti-human antibody (HAHA) antibody titer must be =< 1300 enzyme-linked immunosorbent assay (ELISA) units/mL

TURNSTILE II - TREATMENT:

TURNSTILE II - TREATMENT

Prior treatment with abiraterone or enzalutamide is permitted, but patients must have been off prior corticosteroid treatment for at least 3 months

Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on study except as detailed above

No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613; hydroxyurea and oral tyrosine kinase inhibitors being used without grade =< 2 toxicity can be taken until day 1 of therapy; patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment); patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =< grade 2 are eligible, but must be documented as such

Subjects in whom treatment planning constraints cannot be met

Subjects in whom treatment planning constraints cannot be met

There is no limit to the number of prior systemic treatment regimens

Current treatment on another clinical trial

If a subject is currently receiving bisphosphonates or denosumab, the subject must have received the bisphosphonates or denosumab for at least four weeks before starting study treatment. (Initiation of bisphosphonates or denosumab during the study may be allowed provided the subject completes the first cycle of treatment without any DLT and the Investigator rules out tumor progression.)

For subjects enrolled in the Anastrozole Arm, prior hormonal therapy (including, but not limited to, tamoxifen, megestrol acetate, fulvestrant, and GnRH analogs) for the treatment of recurrent/advanced endometrial cancer are not allowed

Contraindications to treatment with:

Contraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatment

Prior treatment with anti-androgens other than enzalutamide is acceptable

Prior treatment with enzalutamide

Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ? 28 days has elapsed from last dose to study treatment.

Subject has any underlying conditions, which would contraindicate therapy with study treatment

Must have had prior abiraterone treatment

Major active medical or psychosocial problems that could be exacerbated by the study treatment

One or more evaluable or measurable lesions that have progressed based on RECIST 1.1, within 12 months of 131 iodine therapy, despite demonstration of radioiodine avidity at the time of that treatment by pre- or post-treatment scanning. These participants must not be eligible for possible curative surgery; or

Previous treatment with lenvatinib (except for participants previously enrolled into Cohorts 1 or 2B of this study).

Prior treatment with TRC105

Current treatment on another therapeutic clinical trial

Received ? 1 typical regime for the treatment of ITP. Splenectomy is considered one standard ITP treatment

At least two sites of measurable disease as defined by RECIST 1.1; one of which must be amenable to treatment with SAR and accessible for optional pre- and post- treatment biopsy; if a pulmonary nodule is being considered for SAR it must range in size from 1-5 cm

Have provided written consent for mandatory pre- and post-treatment biopsy (expansion cohort only)

Prior treatment with crenolanib with progression on treatment

Prior treatment with talazoparib

Patients with curative treatment options

No prior treatment for myelofibrosis (for cohort 1 only)

Prior treatment with copanlisib

Prolymphocytic leukemia (PLL) T-cell (T)-CLL\r\n* T-PLL: treatment failure after Campath-1H and at least one other regimen\r\n* B-PLL: treatment failure after fludarabine and at least one other salvage regimen

Planned ongoing treatment with other drugs thought to potentially adversely interact with study drugs; if such medications have been used, patients must be off of these agents for >= 2 weeks prior to initiation of treatment:\r\n* Anticoagulants at therapeutic doses\r\n* Immunosuppressants such as tacrolimus, leflunomide or tofacitinib, roflumilast, pimecrolimus

Prior chemotherapy treatment for AML within 21 days from the initiation of HCT conditioning; Note, use of hydroxyurea or other low intensity treatment not intended to induce remission are acceptable

Patients must agree to pre- and post-treatment biopsies

Prior treatment with cabozantinib

Received radionuclide treatment (i.e. iodine [I]-131 meta-iodo-benzyl guanidine) within 6 months of the first dose of study treatment

Patient will have opted for SBRT among definitive treatment choices

TREATMENT: Patients receiving systemic corticosteroid within 48 hours of CTL infusion

Prior local therapy, such as surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment; local therapy must have been completed at least 4 weeks prior to the baseline scan

Any condition that requires or is likely to require treatment with systemic corticosteroids within the core study period and short term follow-up

Subjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study)

Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up

Interested in treatment that might change smoking behavior

Enrolled in another treatment protocol

Patients must be a minimum of 3 weeks from thoracotomy (if performed) and well-healed before starting treatment

Prior treatment with topotecan.

Prior treatment with cytotoxic and biological agents is permissible; there should be at least a 2-week break between prior treatment and the protocol treatment

One prior single fraction radiosurgical procedure within the treatment field is acceptable if V12 < 5 cc (V12 is the volume of normal brain [outside gross tumor volume (GTV)] receiving 12 or more Gy); additional radiosurgical procedures outside of the treatment area are acceptable

Patients who are simultaneously enrolled in any other treatment study

Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; note: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on sonidegib study treatment

Prior treatment with cabozantinib or other c-MET directed therapy

The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment

Receipt of 1 previous systemic drug therapy for at least 3 weeks and withdrawal from treatment due either to intolerability or to radiographic disease progression. If treatment was withdrawn due to intolerability manifested as a Grade 3 or 4 event by National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE v4.0), less than 3 weeks of continuous prior administration prior to withdrawal is acceptable (see also Exclusion Criterion #3).

Locoregional treatment within 4 weeks prior to the Baseline Visit.

Previous treatment with lenalidomide for AML

Prior allograft or prior autograft

Prior treatment with bevacizumab

Patients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing torsades de pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug

Have body temperature >101ºF (38.3ºC) immediately prior to study treatment.

For Cohorts A and B, patients must have progressed on prior treatment with enzalutamide or abiraterone acetate + prednisone (by PSA criteria or radiographically)

For Cohort C (castration-only):\r\n* Patients must continue on castrating therapy throughout BAT treatment\r\n* No prior second line hormone treatment with flutamide, bicalutamide, nilutamide, enzalutamide, abiraterone, ketoconazole, ARN-509 or other investigational androgen ablative therapies is permitted for Cohort C

Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; nota bene (NB): muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatment

Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments

Previous treatment with sunitinib or valproic acid for uveal melanoma

Participants in the study must permit targeted prostate biopsy prior to initiation of study treatment and at the time of fiducial marker placement

Concomitant administration of investigational drugs is not allowed; if investigational drugs were given, their use should be completed as guided by that protocol prior to initiation of cytoreduction on this protocol; if the patient is being treated for secondary (treatment related) myelodysplasia after treatment for a non-hematologic malignancy (e.g. Sarcoma), the primary disease should be in remission for at least 6 months after completing primary therapy; patients with secondary myelodysplasia after treatment of a lymphoma, may proceed with treatment with the lymphoma responding or stable but not progressing

No prior treatment with oxaliplatin, irinotecan (irinotecan hydrochloride), fluorouracil or capecitabine

Prior treatment with cabozantinib

The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment

UGT1A1 genotyping prior to treatment

Refractory to or relapsed after at least 1 prior treatment regimen

Local-regional treatment sites must be able to be encompassed within a reasonable radiation therapy treatment volume

Patients must agree to have a biopsy at baseline and on treatment

Patient who has had prior treatment with demethylating agents

Prior use of venlafaxine specifically for treatment of pain (prior use for treatment of other indications, such as hot flashes, is permitted)

Patient receiving treatment likely to cause hemolysis or under phenytoin treatment.

Only patients that have not received any prior treatment for pancreas cancer are eligible for this treatment protocol

RANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment

Patient must be eligible for HD IL-2 treatment

Relapsed/refractory MCL: Prior treatment with ibrutinib

Prior decitabine for the treatment of cancer

Prior treatment with capecitabine or lapatinib

Biologic therapy (including antibodies [other than trastuzumab], immune modulators, cytokines) within 4 weeks before the first dose of study treatment; Note: there is no washout period required for trastuzumab

Prior treatment with omacetaxine

There will be no limits to prior lines of treatment

Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatment

Patients who have had prior treatment with 131I-MIBG who do not meet the re-treatment criteria

Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted

Patients must be willing to participate in all stages of treatment

Patient is currently benefiting from the treatment with pasireotide, as determined by the investigator

Prior treatment with murine and humanized 3F8 is allowed; patients with prior m3F8, hu3F8, ch14.18 or hu14.18 treatment must have human anti-human antibody (HAHA) antibody titer =< 1300 enzyme-linked immunosorbent assay (Elisa) units/ml; human anti-mouse antibody positivity is allowed

Prior to enrollment, sites must provide evidence of myeloma progression/relapse and evidence of being refractory to lenalidomide, with start and stop dates of lenalidomide therapy and the most recent treatment regimen, as well as best tumor response to all prior treatment regimens

Able to receive outpatient treatment and follow-up at the treating institution.

Prior treatment with eribulin

Allocated to receive Gemcitabine + nab-Paclitaxel as first line treatment.

COHORT 3: ATOPIC DERMATITIS PATIENTS: Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and/or pustules)

Potassium in normal range\r\n* Patients with hypokalemia at screening must be corrected prior to initiating treatment

Patients must not have had prior treatment with floxuridine (FUDR)

Prior thoracic radiation allowable only if there is minimal to no overlap with the treatment area estimated at the time of consultation

However, abnormalities of specific organs will not be considered grounds for exclusion if they are the result of the EBV+ malignancy or its treatment (e.g. a renal allograft recipient with an EBVLPD may be on dialysis because the allograft was rejected when the immune suppression was stopped as a first approach to treatment of the EBVLPD); a the discretion of the investigator, patients with elevated but stable creatinine will not be precluded from treatment on study

Able to tolerate pre / post - procedure steroid treatment

Temozolomide re-treatment is planned by the treating neuro-oncologist

Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities)

Prior history of treatment with ponatinib

Prior treatment with murine 3F8 is allowed; patients with prior m3F8, chimeric (ch)14.18 or hu14.18 treatment must have human anti-hu3F8 antibody (HAHA) antibody titer less than the upper limit of normal (defined as mean + 3*standard deviation [SD] of normal volunteers)

Prior systemic treatment with an azole anti-fungal drug (e.g. fluconazole, itraconazole) within 4 weeks of cycle 1, day 1

Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of mCRPC.

Prior treatment with agents targeting the VEGF pathway, including bevacizumab

Prior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine.

Previous systemic anti-cancer therapy for T-cell lymphoma must have been discontinued at least 3 weeks prior to treatment; for the dose expansion phase, in progressing subjects, a 2 week washout may be allowed after discussion with Memorial Sloan-Kettering (MSK) principal investigator

Has been treated with an Somatostatin analogs (SSA) at any time prior to randomization, except if that treatment was for less than 15 days (e.g. peri-operatively) of short acting SSA or one dose of long acting SSA and the treatment was received more than 6 weeks prior to randomization

Patients must have an ECOG PS of 0-1 at screening and on the day prior to treatment.

Not currently a candidate for curative treatment

Received an immune-suppressive based treatment for any reason within 14 days prior to the first dose of study treatment.

Must not have experienced an immune-related adverse event (irAE) where the irAE was the reason for permanent discontinuation of prior immunotherapy in the most recent prior treatment regimen

Patients currently receiving chronic corticosteroid treatment (longer than 8 weeks duration) for management of pre-existing adverse events, or patients with a history of chronic corticosteroid treatment longer than 8 weeks' duration for AEs within 6 months of Screening are excluded

Adults with AML in need of treatment

Unable to receive prophylactic treatment for pneumocystis

TREATMENT:

Prior treatment with irinotecan and/or bevacizumab

Patients receiving chronic treatment with systemic steroids; however, patients can receive up to 10 days of steroid therapy prior to starting treatment with brentuximab vedotin (BV)+ doxorubicin, vinblastine, dacarbazine (AVD)

Treatment plan that includes regional nodal irradiation

No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator’s opinion

Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on study

Prior treatment with other immunotherapy, including antibodies, is allowed

Patients cannot take any additional vitamin D supplementation during study treatment; patients taking > 2000 IU per day prior to treatment will be ineligible

Additional treatment for NHL administered from time of autologous SCT through registration

Patients must be or have been ambulatory within a week prior to treatment

No planned systemic treatment is allowed within one week after treatment

Patients must be willing to participate in all stages of treatment

Subjects must have an indication for treatment as defined by the NCI Working Group Guidelines

Life expectancy reasonably adequate for evaluating the treatment effect

Prior treatment with idelalisib

Patients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have declined treatment

Previous treatment with gene therapy

Patient has had previous treatment with poziotinib.

Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatment

Ongoing or previous anti-cancer treatment within 4 weeks before randomization.

Previous treatment with ixazomib, or participated in a blinded study with ixazomib

Refractory to or relapsed after at least 1 prior treatment regimen

Refractory to first or later treatment, or

Previous treatment with any anti-CD40 antibody.

Prior treatment with anti-lymphocyte globulin or anti-thymocyte globulin

Prior treatment for rectal cancer.

Current treatment of at least 3 months with pembrolizumab or nivolumab (no more than 1 cycle / 6 weeks of treatment interruption immediately prior to study enrollment)

Patients in which treatment with pembrolizumab and nivolumab is contraindicated

Patients must have received prior treatment with an immunomodulatory drug (IMiD) (for ?2 cycles or ?2 months of treatment) and a proteasome inhibitor (PI) (for ?2 cycles or ?2 months of treatment).

Planned neoadjuvant chemoRT treatment must conform to NCCN guidelines.

Inclusion Criteria:\n\n        Cohort A (Solid Tumours)\n\n          -  Age >= 18 years (>=20 years for Japan only) at screening\n\n          -  Signed and dated written informed consent in accordance with GCP (Good Clinical\n             Practice and local legislation prior to admission to the trial\n\n          -  WHO/ECOG (World Health Organization / Eastern Cooperative Oncology Group) performance\n             status 0-1 assessed at screening\n\n          -  Patient must be able to swallow oral capsules.\n\n          -  Male or female patients ready and able to use highly effective methods of birth\n             control during the study and for 12 weeks following the last dose of abemaciclib per\n             ICH (International Conference on Harmonization) M3(R2) that result in a low failure\n             rate of less than 1% per year when used consistently and correctly. A list of\n             contraception methods meeting these criteria is provided in the patient information.\n             Women of childbearing potential must have a negative serum pregnancy test at\n             screening.\n\n          -  Patients with histologically or cytologically confirmed diagnosis of advanced and/or\n             metastatic, measurable or evaluable, non-resectable solid tumours\n\n          -  Patients must have received and failed, or have been intolerant to, all treatment\n             known to confer clinical benefit or have no therapeutic options available as deemed\n             appropriate by their treating physician\n\n          -  Life expectancy >= 3 months in the opinion of the investigator assessed at screening;\n\n        Cohorts B, C, D, F (Breast Cancer):\n\n          -  Age >= 18 years (>=20 years for Japan only) at screening\n\n          -  Signed and dated written informed consent in accordance with GCP and local legislation\n             prior to admission to the trial\n\n          -  WHO/ECOG performance status 0-1 assessed at screening\n\n          -  Patient must be able to swallow oral capsules.\n\n          -  Women who have postmenopausal status due to either surgical/natural menopause or\n             chemical ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1)\n             with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or\n             radiation-induced ovarian suppression\n\n               -  postmenopausal status defined as meeting one of the following conditions:\n\n                    -  prior bilateral oophorectomy\n\n                    -  age >= 60 years\n\n                    -  age < 60 years and amenorrheic (non-treatment-induced amenorrhea secondary\n                       to tamoxifen, toremifene, ovarian suppression, or chemotherapy) for at least\n                       12 months; and follicle stimulating hormone (FSH) and estradiol within the\n                       postmenopausal range as per institutional reference ranges.\n\n               -  Postmenopausal status due to radiation-induced ovarian suppression must be\n                  confirmed by FSH and estradiol level in the postmenopausal range\n\n          -  Histologically or cytologically proven diagnosis of breast cancer with evidence of\n             locally advanced or metastatic disease not amenable to resection or radiation\n\n          -  HR+ (local lab results at screening or, if not available, at the time of diagnosis) To\n             fulfil the requirement of HR+ disease, the primary tumour or metastatic lesion of the\n             breast cancer must express at least one of the hormone receptors (estrogen receptor\n             [ER] or progesterone receptor [PgR]) by immunohistochemistry (IHC). Estrogen receptor\n             and PgR assays are considered positive if there are at least 1% positive tumour nuclei\n             in the sample as defined in the relevant American Society of Clinical Oncology\n             (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).\n\n          -  HER2 negative (local lab results at screening or, if not available, at the time of\n             diagnosis) as defined by the most recent American Society of Clinical Oncology\n             (ASCO)/College of American Pathologists (CAP) Guidelines (Hammond et al. 2010).\n\n          -  Previous adjuvant and neoadjuvant chemotherapy is permitted. 0-2 prior lines of\n             chemotherapy for the metastatic setting are allowed.\n\n          -  At least 1 lesion (measurable or non-measurable) that can be accurately assessed at\n             baseline with CT or MRI or PET-CT (CT portion of diagnostic quality) and which is\n             suitable for accurate repeated measurement. For Cohort F only: patients should have at\n             least one measurable lesion.\n\n          -  Cohort B, C, D, F Must be eligible for the corresponding hormonal therapy (letrozole,\n             anastrozole or fulvestrant). For Cohorts B and C previous treatment with fulvestrant\n             or exemestane is allowed. For Cohort D and F prior therapy with non steroidal\n             aromatase inhibitors (anastrozole, letrozole) or exemestane are permitted\n\n          -  Cohort F only: Postmenopausal with locally advanced or metastatic HR+ breast cancer\n             and refractory to aromatase inhibitors therapy and CDK4/6 inhibitor treatment (e.g.,\n             palbociclib or ribociclib) for locally advanced or metastatic breast cancer.Resistance\n             to aromatase inhibitors therapy is defined as the following:\n\n               -  disease recurrence while on, or within 12 months of end of adjuvant treatment\n                  with letrozole, anastrozole, or exemestane;\n\n               -  or disease progression while on, or within one month of end of letrozole,\n                  anastrozole, or exemestane.\n\n        Cohort E (NSCLC (Non-Small Cell Lung Cancer)):\n\n          -  Age >= 18 years (>=20 years for Japan only) at screening\n\n          -  Signed and dated written informed consent in accordance with GCP and local legislation\n             prior to admission to the trial\n\n          -  WHO/ECOG performance status 0-1 assessed at screening\n\n          -  Patient must be able to swallow oral capsules.\n\n          -  Male or female patients ready and able to use highly effective methods of birth\n             control during the study and for 12 weeks following the last dose of abemaciclib per\n             ICH M3 (R2) that result in a low failure rate of less than 1% per year when used\n             consistently and correctly. A list of contraception methods meeting these criteria is\n             provided in the patient information. Women of childbearing potential must have a\n             negative serum pregnancy test at screening.\n\n          -  Histologically or cytologically confirmed diagnosis of stage IV NSCLC.\n\n          -  The participant must have progressed after platinum-based chemotherapy AND\n             immunotherapy (unless deemed inappropriate candidates for immunotherapy by their\n             treating physician) AND have received a maximum of 2 other prior chemotherapy for\n             advanced and/or metastatic disease OR must be judged by the physician as ineligible\n             for further standard second-line chemotherapy. Prior treatment with epidermal growth\n             factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and anaplastic lymphoma kinase\n             (ALK) inhibitors is mandatory in participants whose tumour has EGFR-activating\n             mutations or ALK translocations. Prior targeting agents and neoadjuvant/adjuvant\n             therapies are permitted.\n\n          -  Have adequate organ function including haematology, renal, and liver.\n\n          -  Have measureable disease per Response Evaluation Criteria In Solid Tumours (RECIST)\n             1.1.\n\n        Exclusion Criteria:\n\n        All cohorts:\n\n          -  Any documented active or suspected malignancy or history of malignancy, other than the\n             disease under study, within 3 years prior to screening, except appropriately treated\n             basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or ductal\n             carcinoma in situ (DCIS) if properly treated in opinion of the investigator.\n\n          -  Patients who must or wish to continue the intake of restricted medications or any drug\n             considered likely to interfere with the safe conduct of the trial\n\n          -  Previous treatment in this trial\n\n          -  Currently enrolled in another investigational device or drug study, or less than 21\n             days since ending another investigational device or drug study(s), or receiving other\n             investigational treatment(s).\n\n          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,\n             makes them an unreliable study subject or unlikely to complete the trial\n\n          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.\n             Men who plan to father a child while in the trial.\n\n          -  Prior chemotherapy, biological or radiation therapy, androgens, thalidomide, other\n             anticancer agents, or any investigational drug within 21 days; and/or three half-lives\n             for immunotherapy, before starting any of the trial drugs.\n\n          -  Prior anti CDK (Cyclin-dependent Kinase) agents (except cohort F)\n\n          -  Prior radiotherapy to >= 25% of bone marrow regardless of when it was received\n\n          -  Unresolved treatment related toxicity from previous therapy of > CTCAE grade 1 at\n             study entry (except for stable sensory neuropathy ? CTCAE grade 2 and alopecia)\n\n          -  Previous treatment with IGF (Insulin-like Growth Factor)-1R targeting compounds\n\n          -  Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or\n             leptomeningeal disease, as indicated by clinical symptoms, cerebral oedema, and/or\n             progressive growth. History of CNS metastases or cord compression are eligible if they\n             have been definitively treated (e.g. radiotherapy, stereotactic surgery) and are\n             clinically stable, off anticonvulsants and steroids for at least 4 weeks. Patients\n             with brain metastases are eligible if they are asymptomatic or treated at a stable\n             dose of steroids for at least 4 weeks. Patients are not eligible if they have spinal\n             cord compression.\n\n          -  Any evidence of severe or uncontrolled systemic disease as judged by the Investigator.\n\n          -  Inadequate bone marrow reserve or organ function as demonstrated by any of the\n             following: ANC < 1.5 x 109/L, platelets < 100 x 109/L, haemoglobin <90g/L, ALT > 2.5 x\n             ULN or > 5 x ULN in the presence of liver metastases, total bilirubin >1.5 x ULN or >3\n             x ULN in patients with Gilbert's Syndrome, serum creatinine > 1.5 x ULN concurrent\n             with creatinine clearance <= 50 mL/min.\n\n          -  Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi\n             Syndrome or renal tubular acidosis\n\n          -  Refractory nausea and vomiting, chronic GI diseases, inability to swallow the product,\n             or previous significant bowel resection that would preclude adequate absorption of\n             abemaciclib or resulting in baseline Grade 2 or higher diarrhoea.\n\n          -  History of hypersensitivity to active or inactive excipients of xentuzumab,\n             abemaciclib or letrozole/anastrozole/fulvestrant, or loperamide hydrochloride, or\n             drugs with similar chemical structures\n\n          -  Patients with Diabetes Type I or uncontrolled Type II (defined by HgBA1C > 8%)\n\n          -  Patients with advanced/metastatic, symptomatic, visceral spread, that are at risk of\n             life threatening complications in the short term including patients with massive\n             uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and\n             over 50% of liver involvement in metastases.\n\n          -  Prior hematopoietic stem cell or bone marrow transplant\n\n          -  Have a personal history of any of the following conditions: syncope of either\n             unexplained or cardiovascular etiology, ventricular arrhythmia (including but not\n             limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac\n             arrest. Subjects with controlled atrial fibrillation for >30 days prior to study\n             treatment are eligible.\n\n          -  Erythropoietin, G-CSF, and GM-CSF are not allowed within 2 weeks prior to study. The\n             primary prophylactic use of G-CSF is not permitted but it may be used to treat\n             treatment emergent neutropenia.\n\n          -  Have had major surgery (excluding biopsy) < 28 days of the initial dose of any of the\n             study drugs or planned major surgery during study participation.\n\n          -  Have active bacterial, fungal, and/or known viral infection (for example, human\n             immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen, or hepatitis C\n             antibodies). Screening is not required for enrolment.\n\n          -  Patients with baseline Grade >=2 hyperglycaemia or patients with baseline Grade >= 2\n             diarrhoea\n\n          -  Patients needing treatment with CYP3A4 inhibitors/inducers cannot be included in the\n             trial.

Loco-regional treatment within 4 weeks prior to initiation of study treatment.

Prior treatment with a HER3 antibody

Patient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment.

Patient has been permanently and prematurely discontinued from ceritinib study treatment in the parent study due to any reason.

Primary hepatic dysfunction including known cirrhosis or active hepatitis. Patients with biliary obstruction must be stented prior to initiating treatment.

Previous treatment for NHL

Treatment with drugs that have the potential to interfere with metabolism or excretion of mibefradil

Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment

Previous discontinuation of treatment with deferiprone or deferoxamine due to adverse events;

Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment.

Patient has been permanently discontinued from everolimus study treatment in the parent study.

Patient is receiving everolimus in combination with an unapproved or experimental treatment

Inclusion Criteria:\n\n        -Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development &\n        Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the\n        parent study -Patient is currently benefiting from the treatment with nilotinib, as\n        determined by the investigator -Patient has demonstrated compliance, as assessed by the\n        investigator, with the parent study protocol requirements -Willingness and ability to\n        comply with scheduled visits, treatment plans and any other study procedures -Written\n        informed consent obtained prior to enrolling in roll-over study\n\n        Exclusion Criteria:\n\n        - Patient has been permanently discontinued from nilotinib treatment in the parent study\n        due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or\n        any other reason - Patient has participated in a Novartis sponsored combination trial where\n        nilotinib was dispensed in combination with another study medication and patient is still\n        receiving combination therapy -Patients who are currently receiving treatment with any\n        medications that have the potential to prolong the QT interval or inducing Torsade de\n        Pointes and the treatment cannot be either safely discontinued at least one week prior to\n        nilotinib treatment or switched to a different medication prior to start of nilotinib\n        treatment and for the duration of the study -Pregnant or nursing (lactating) women, where\n        pregnancy is defined as the state of a female after conception and until the termination of\n        gestation, confirmed by a positive hcG laboratory test. -Women of child-bearing potential,\n        defined as all women physiologically capable of becoming pregnant, unless they are using\n        highly effective methods of contraception during the study and for 30 days after the final\n        dose of nilotinib.

Prior Temozolomide treatment

Treatment with chronic immunosuppressants

Patients who are currently receiving treatment with medication that has the potential to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug

Need for other anticancer treatment

Prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other than a vinca alkaloid

More than 3 painful lesions or more than 2 requiring immediate localized treatment

Change in the symptomatic treatment of mastocytosis or administration of any new treatment of mastocytosis within 4 weeks prior to baseline

Previous or current treatment with mitotane or other antineoplastic drugs for ACC

Patients who have completed the End of Treatment assessments in their originating study. Every effort should e made to conduct the End of Treatment visit such that the patient does not have any interruption in sorafenib dosing.

Patient on active current treatment of antiplatelet agents (i.e. off-study Aspirin, clopidogrel, ticlopidine)

At study entry, participants must be actively receiving treatment with single-agent PCI-32765 or participants must have participated in a PCI-32765 randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of 6 months requirement for prior PCI-32765 treatment will not be mandatory in this case and participants with less than 6 months will be required to have more frequent initial safety assessments

Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.

Currently tolerating treatment in the parent protocol.

Has been permanently discontinued from study treatment in the parent study for any reason.

Subjects cannot be simultaneously enrolled on other treatment studies

Current treatment in another clinical study

105 For DLBCL: Refractory (no prior CR/CMR) to first or later line of treatment or relapsed (prior CR/CMR) after two or more prior treatments., with at least one treatment consisting of standard multiagent chemotherapy containing an anthracycline AND an approved anti-CD20 agent. Examples of appropriate therapy include but are not limited to R-CHOP (14 or 21), R-CHOEP, and DA-REOCH. For FL: Refractory (no prior CR/CMR) to first or later line of treatment or relapsed (prior CR/CMR) after two or more prior treatments, with at least one treatment consisting of a standard chemotherapy containing an approved anti-CD20 agent. Examples of appropriate therapy include but are not limited to R-CHOP, R-CVP, and BR. For MCL: Refractory (no prior CR/CMR) to first or later line of treatment or relapsed (prior CR/CMR) after two or more prior treatments, with at least one treatment consisting of a standard chemotherapy containing an approved anti-CD20 agent. Examples of appropriate therapy include but are not limited to R-CHOP, BR and hyper-CVAD alternating with R-MTX/Ara-C. For subjects with refractory B-NHL and who have received radiotherapy, PET positivity should be demonstrated no less than 6 weeks after the last dose of radiotherapy

Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of study treatment

Previous treatment must include treatment with a single line of chemoimmunotherapy containing an anthracycline and a CD20-targeted agent

Previous treatment with CD19-targeted therapy, with the exception of prior lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment

Had prior treatment with napabucasin.

No prior treatment with wee1 kinase inhibition

Must not require concomitant treatment with anticoagulants

3. Morphologically documented relapsed/refractory AML as defined by World Health Organization (WHO) criteria after at least 1 prior therapy for AML with the exception of hydroxyurea, and not felt to have curative treatment options per treating physician, or the patients themselves are unwilling to consider curative treatment options.

Cancer-directed therapy within 2 weeks prior to starting treatment, with the exception of hydroxyurea, which is allowed to control white blood cell count. Hydroxyurea will be weaned as soon as clinically feasible.

Prior treatment with TAS-102 or regorafenib

Additional Exclusion Criteria for subjects Assigned to Treatment A: Subjects unable to tolerate antithrombotic prophylaxis must be excluded; Discontinuation of prior treatment with lenalidomide due to intolerable AEs.

Additional Exclusion Criteria for Subjects Assigned to Treatment B: Unacceptable AEs from previous bortezomib treatment; Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous bortezomib treatment; Intolerance or contraindications to anti-viral prophylaxis.

Prior treatment with sipuleucel-t and Ra-223 is permitted, provided there has been a two-week washout from the last dose

Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (irTEAEs)

Previous treatment with idelalisib at any time (ZYDELIG®)

Prior treatment with SERMs or SERDs within 5 weeks of first G1T48 dose

Dose level 2 (20 mg) and higher: willing to provide baseline and on treatment tumor biopsies (3 weeks after RXDX-106 treatment initiation), provided the procedure is clinically feasible and not deemed unsafe by the investigator.

Availability of production capacities for the patient's IMA202 product prior to the leukapheresis TREATMENT SCREENING:

Minimum intervals required to be off treatment prior to Cycle 1 Day 1:

No limits to the prior lines of treatment

Predicted time to first treatment of ?3 years according to MDACC nomogram.

Treatment with corticosteroids other than physiological replacement within the previous week or treatment with immunosuppressive medication within the previous week.

Subjects must be primary refractory or relapsed to 1st line intensive treatment for AML or refractory or relapsed after second line of treatment for AML

Previous treatment with crenolanib or prior participation in clinical trial involving crenolanib.

Patients having received prior radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy within the 2 weeks prior to treatment with CPI-613, or those who have not fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)

Using any systemic treatment for BCC (e.g. vismodegib), or any topical treatment for their BCC tumors, unless discontinued at least one month prior

REGISTRATION TO TREATMENT (STEP 1): No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment; patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation

REGISTRATION TO TREATMENT (STEP 2): No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment; patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation

Prior PARP therapy could have been administered as either treatment for recurrent disease or as maintenance following prior treatment.

Patients with prior treatment with idelalisib.

Previous treatment with talimogene laherparepvec or any other oncolytic virus

Sexually active subjects and their partners unwilling to use a male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec

Subjects in expansion cohort only: Willing to undergo pre- and on-treatment biopsies

Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted. Prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is > 3 years.

Any other experimental treatment on another clinical trial

Prior treatment with trabectedin or trabectedin analog

Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment

Has had prior treatment with idelalisib

RENAL COHORT: Any number of prior treatment lines is allowed on study

BLADDER: The patient must be systemic treatment naive, previous intra-vesicle therapy is allowed

Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)

Previous assignment to treatment during this study; patients permanently withdrawn from study participation will not be allowed to re-enter the study

Prior radiation which overlaps and precludes hypofractionated treatment to the index lesion

Prior treatment with drug targeting cyclin-dependent kinase (CDK) family

All patients must consent to pre-treatment biopsy of the tumor if it can be done safely (as judged by the investigator) during screening. Week 10 on-treatment biopsies will be required for a minimum 10 patients. After 10 paired biopsies have been obtained then week 10 on-treatment biopsy will be made optional.

Patients with spinal cord compression or a history of leptomeningeal carcinomatosis. At the time of day 1 of the study, patients with central nervous system metastases must have been treated and must be asymptomatic and meet the following criteria. 1. No concurrent treatment, inclusive of, but not limited to, surgery, radiation, and/or corticosteroids. (Note: patients are allowed on systemic steroids unless these are being administered to manage central nervous system metastases); 2. Neurologic stability (lack of signs or symptoms greater than baseline prior to radiotherapy) until the time of dosing of MEDI0457; 3. For radiation treatment, patients must be: at least 14 days between last day of stereotactic radiosurgery or gamma-knife treatment and day 1 of protocol treatment, at least 28 days between last day of whole brain radiation therapy and day 1 of protocol treatment, and/or at least 14 days since last dose of corticosteroids and day 1 of protocol treatment.

Patient is on any systemic corticosteroid therapy within one week before the planned date for first dose of treatment or on any other form of immuno-suppressive medication

ENROLLMENT: Patient must have fully recovered (i.e. returned to baseline) from the clinically significant acute treatment-related toxicities of all prior treatments prior to beginning treatment on this protocol with exceptions of cytopenias resulting from persistent disease, hearing loss and alopecia.

Patients receiving any other standard or investigational treatment for their cancer with a primary goal of improving survival within the past 2 weeks prior to initiation of CPI-613 treatment

Prior treatment with docetaxel or cabazitaxel for mCRPC

Prior systemic treatment

Patient is currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and whose treatment cannot be either discontinued or switched to a different medication prior to starting treatment with the study drug.

Patient has received enzalutamide for the treatment of prostate cancer; however, previous treatment with other hormonal therapy (bicalutamide, flutamide, nilutamide, abiraterone and ketoconazole) or chemotherapy (docetaxel, cabazitaxel or mitoxantrone) is allowed

Willingness to undergo fluoroscopy-guided SGB or sham treatment

Any anti-lymphoma treatment within 6 months of treatment initiation.

Previous treatment with cetuximab with evidence of clinical benefit, as defined by complete response, partial response, or prolonged stable disease with 16 or more weeks of treatment without radiographic progression, as assessed by the treating physician and documented in the medical record; this treatment may have occurred at any point in the patient’s clinical course for treatment of metastatic colorectal cancer

Patient who is currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study

Patients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug

Subjects must agree to undergo two research-directed biopsies during treatment

Started or planning to start on strenuous exercise regimen after first dose of study treatment (i.e., muscular activities, such as strenuous exercise, that can result in significant increase in plasma CK levels should be avoided while on trametinib treatment)

Clinical indication for treatment with azacitidine.

Hydroxyurea within 48 hours prior to first day of study treatment.

Current unstable arrhythmia requiring treatment.

Subjects must have failed prior therapy with abiraterone, enzalutamide, or both: has completed at least 12 weeks of prior continuous therapy with abiraterone or enzalutamide; has not been without abiraterone or enzalutamide treatment for >30 days prior to initiation of study treatment; lead-in dosing period for enzalutamide only will be required under the following circumstance:

Prior treatment: Treated with two or more lines of prior therapy, with disease refractory to both a proteasome inhibitor and an immunomodulatory agent, and disease progression (as defined by International Myeloma Working Group (IMWG) criteria) following treatment with an anti-CD38 monoclonal antibody given as monotherapy or in combination therapy. The most recent treatment regimen must have contained an anti-CD38 monoclonal antibody.

Patient has documented pneumonitis which is active and requiring treatment

Treatment with abiraterone within 2 weeks prior to study treatment

Prior treatment for study indication with:

Prior treatment with CD47 or signal regulatory protein alpha (SIRP?) targeting agents

Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions other than CMV when study treatment is initiated (example: herpes simplex virus (HSV) coinfection requiring use of any of these agents after the randomization) or would need a coadministration with maribavir for CMV infection. NOTE: A subject who is not continuing with the same anti-CMV drug(s) (ganciclovir, valganciclovir or foscarnet) for the study treatment (if randomized to the investigator assigned anti-CMV treatment arm), must discontinue their use before the first dose of study drug. If subject is currently being treated with cidofovir and is assigned another anti-CMV therapy by the investigator, the subject must discontinue its use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment.

Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated. NOTE: Subjects who may be receiving leflunomide or letermovir must discontinue the use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study treatment. Subjects receiving artesunate must discontinue the use prior to the first dose of study treatment.

Subjects who may still be sensitive to repeated treatment with decitabine or azacitidine such as subjects who had response to prior decitabine or azacitidine treatment, but relapsed >6 months after stopping treatment with these agents.

Prior treatment with guadecitabine.

Inclusion Criteria:\n\n        Subjects must satisfy the following criteria to be enrolled in the study:\n\n          1. Subject is ? 18 years of age the time of signing the informed consent form (ICF).\n\n          2. Subject must understand and voluntarily sign an ICF prior to any study-related\n             assessments/procedures being conducted.\n\n          3. Subject is willing and able to adhere to the study visit schedule and other protocol\n             requirements.\n\n          4. Subject has newly diagnosed, primary (ie, de novo) or secondary (progression of MDS or\n             myeloproliferative neoplasms [MPN], or therapy-related) AML according to the WHO\n             classification with ? 20% leukemic blasts in the bone marrow: -Have an Isocitrate\n             dehydrogenase 1 (IDH1) or Isocitrate dehydrogenase 2 (IDH2) gene mutation (R132, R140,\n             or R172)\n\n               -  IDH mutational status will be assessed locally; for sites without local testing\n                  capabilities, a referral lab will be identified.\n\n                    -  By the investigator's assessment who are not candidates to receive intensive\n                       Inductive chemotherapy (IC).\n\n          5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or\n             2.\n\n          6. Subject has adequate organ function defined as:\n\n               -  Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase\n                  (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? 3 x ULN, unless considered\n                  due to leukemic organ involvement.\n\n               -  Serum total bilirubin < 1.5 x ULN. Higher levels are acceptable if these can be\n                  attributed to ineffective erythropoiesis, 3 times the upper limit of normal for\n                  Gilbert's syndrome (eg, a gene mutation in UGT1A1), or leukemic organ\n                  involvement.\n\n               -  Serum creatinine < 2 x ULN or creatinine clearance > 30 mL/min based on the\n                  Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR):\n\n             GFR (mL/min/1.73 m2) = 175 × (Scr)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if\n             African American)\n\n          7. Agree to serial bone marrow aspirate/biopsies.\n\n          8. Females of childbearing potential (FCBP)* may participate, providing they meet the\n             following conditions:\n\n               -  Agree to practice true abstinence ** from sexual intercourse or to use highly\n                  effective contraceptive methods (eg, combined [containing estrogen and\n                  progestogen] or progestogen only associated with inhibition of ovulation, oral,\n                  injectable, intravaginal, patch, or implantable hormonal contraceptive; bilateral\n                  tubal occlusion; intra-uterine device; intrauterine hormone-releasing system; or\n                  male partner sterilization [note that a vasectomized partner is a highly\n                  effective birth control method provided that partner is the sole sexual partner\n                  of the FCBP trial participant and that a vasectomized partner has received\n                  medical assessment of the surgical success]) at screening and throughout the\n                  study, and for at least 4 months following the last study treatment; and\n\n               -  Have a negative serum ?-subunit of human chorionic gonadotropin (?-hCG) pregnancy\n                  test (sensitivity of at least 25 mIU/mL) at screening; and\n\n               -  Have a negative serum or urine (investigator's discretion under local\n                  regulations) ?-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72\n                  hours prior to the start of study treatment in the Treatment Period (note that\n                  the screening serum pregnancy test can be used as the test prior to the start of\n                  study treatment in the Treatment Period if it is performed within the 72-hour\n                  timeframe).\n\n          9. Male subjects must agree to practice true abstinence from sexual intercourse or agree\n             to the use of highly effective contraceptive methods (as described above) with\n             non-pregnant female partners of child bearing potential at screening and throughout\n             the course of the study and should avoid conception with their partners during the\n             course of the study and for at least 4 months following the last study treatment (6\n             months following last dose of azacitidine in Canada). Furthermore, the male subject\n             must agree to use a condom while treated with azacitidine and for at least 4 months\n             following the last azacitidine dose.\n\n        Exclusion Criteria:\n\n        - The presence of any of the following will exclude a subject from enrollment:\n\n          1. Subject is suspected or proven to have acute promyelocytic leukemia based on\n             morphology, immunophenotype, molecular assay, or karyotype.\n\n          2. Subject has AML secondary to chronic myelogenous leukemia (CML).\n\n          3. Subject has received a targeted agent against an Isocitrate dehydrogenase 1 (IDH1) or\n             Isocitrate dehydrogenase 2 (IDH2) mutation.\n\n          4. Subject has received prior systemic anticancer therapy, HSCT, or radiotherapy for AML.\n\n             Note: Hydroxyurea is allowed prior to enrollment for the control of peripheral\n             leukemic blasts in subjects with leukocytosis. (however, hydroxyurea should not be\n             given within 72 hours prior to and after administration of azacitidine). For subjects\n             with secondary AML (eg, MDS or MPN) treatment for prior cancer is not exclusionary;\n             full treatment information will be collected within the CRF. The use of all trans\n             retinoic acid (ATRA) for suspected APL is not exclusionary provided it is discontinued\n             prior to initiation of treatment in the protocol.\n\n          5. Subject has received more than 1 cycle of prior treatment with azacitidine, or subject\n             has received any prior treatment with decitabine for Myelodysplastic syndromes (MDS).\n\n             - Clarification: Subjects with newly diagnosed Acute myeloid leukemia (AML) who are\n             currently receiving their 1st cycle of azacitidine (7 days) can be screened for the\n             study. On study, Cycle 1 must be started at 28 days (+/- 3 days) after initiation of\n             the pre-study azacitidine.\n\n          6. Subject has or is suspected of having central nervous system (CNS) leukemia.\n             Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is\n             suspected during screening.\n\n          7. Subject has immediate life-threatening, severe complications of leukemia such as\n             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated\n             intravascular coagulation.\n\n          8. Subject has significant active cardiac disease within 6 months prior to the start of\n             study treatment, including New York Heart Association (NYHA) class III or IV\n             congestive heart failure; acute coronary syndrome (ACS); and/or stroke; or left\n             ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated\n             acquisition (MUGA) scan obtained within 28 days prior to the start of study treatment.\n\n          9. Subject has prior history of malignancy, other than MDS, Myeloproliferative neoplasm\n             (MPN), or AML, unless the subject has been free of the disease for ? 1 year prior to\n             the start of study treatment. However, subjects with the following history/concurrent\n             conditions are allowed:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix\n\n               -  Carcinoma in situ of the breast\n\n               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,\n                  node, metastasis clinical staging system)\n\n         10. Subject is known seropositive for or has active viral infection with human\n             immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or\n             hepatitis C virus (HCV)\n\n         11. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other\n             conditions that limit the ingestion or gastrointestinal absorption of drugs\n             administered orally\n\n         12. Subject has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or\n             diastolic BP > 100 mmHg)\n\n         13. Subject is taking the following sensitive CYP substrate medications that have a narrow\n             therapeutic range are excluded from the study unless the subject can be transferred to\n             other medications at least 5 half-lives prior to the start of study treatment:\n             phenytoin (CYP2C9), S-mephenytoin (CYP2C19), thioridazine (CYP2D6), theophylline, and\n             tizanidine (CYP1A2).\n\n         14. Subject is taking the breast cancer resistance protein (BCRP) transporter-sensitive\n             substrate rosuvastatin; subject should be excluded from the study unless he/she can be\n             transferred to other medications at least 5 half-lives prior to the start of study\n             treatment.\n\n         15. Subject has active uncontrolled systemic fungal, bacterial, or viral infection\n             (defined as ongoing signs/symptoms related to the infection without improvement\n             despite appropriate antibiotics, antiviral therapy, and/or other treatment).\n\n         16. Subject has known or suspected hypersensitivity to any of the components of study\n             therapy.\n\n         17. Subject is taking medications that are known to prolong the QT interval unless he/she\n             can be transferred to other medications within ? 5 half-lives prior to the start of\n             study treatment.\n\n         18. Subject has Heart rate-corrected QT (QTc) interval (ie, Fridericia's correction\n             [QTcF]) ? 450 ms or other factors that increase the risk of QT prolongation or\n             arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval\n             syndrome) at screening.\n\n         19. Female subject who is pregnant or lactating.\n\n         20. Subject has any significant medical condition, laboratory abnormality, or psychiatric\n             illness that would prevent the subject from participating in the study.\n\n         21. Subject has any condition, including the presence of laboratory abnormalities that\n             places the subject at unacceptable risk if he/she were to participate in the study.\n\n         22. Subject has any condition that confounds the ability to interpret data from the study.

Prior treatment with cabozantinib

The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment

Presence of biopsiable disease and patient able to undergo pre-treatment and on-treatment biopsy

Have been informed of other treatment options

Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1

Patients with prior treatment with hypomethylating agents

Previous treatment with talimogene laherparepvec (T-VEC) or any other oncolytic virus

Prior treatment with a CD123xCD3 bispecific agent, T cells expressing CD123 specific chimeric antigen receptor, or toxin-conjugated to CD123 antibodies; prior treatment with naked anti-CD123 monoclonal antibody is permitted

Progression at any time after initiation of azacitidine or decitabine treatment OR

Serum calcium (corrected for albumin) level above the ULN range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with standard treatment).

TREATMENT: Patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment, denosumab, or similar agents are eligible to participate and may continue this treatment; patients with prostate cancer may continue LHRH agonists or antagonists

Subjects must be willing to undergo 2 sets of core needle biopsies (pre-treatment and on-treatment), if there are lesions amenable to biopsy; an optional core biopsy will be requested at progression

Prior systemic therapy directed at advanced RCC is not allowed for patients enrolled to the expansion cohort, treatment naive arm; if prior (neo)adjuvant treatment given as part of a clinical trial, this would be allowed as long as last dose was > 1 year prior to start of treatment

Prior treatment with pomalidomide

Planning to embark on a new strenuous exercise regimen after first dose of study treatment; NOTE: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on binimetinib treatment

Prior treatment with docetaxel.

Previous treatment with TAS-102 or TMZ

Prior treatment with fluoropyrimidines (applicable to Part 1 only)

Subjects for whom a potential 29-day delay in treatment will interfere with the subject’s potential therapeutic options

Previous first line treatment with at least standard dose of radiotherapy (total dose >= 54 Gy) and temozolomide

Has prior treatment with Gliadel unless it was administered as first line treatment and at least 3 months prior to study treatment

Participants are allowed to receive, but are not required to receive, biologic/targeted (noncytotoxic) therapy as part of their primary treatment regimen

Any previous treatment with vosaroxin

Patients that have previously progressed on pomalidomide treatment

Prior treatment, involving interferon, anakinra, imatinib, steroids, chemotherapy with, but not limited to cladribine, vinblastine, 6-mercaptopurine and etoposide, or other medications used empirically for the treatment of ECD, will be acceptable; these therapies should have been completed and discontinued 4 weeks or more prior to enrollment in this study

A treatment regimen containing ibrutinib unless patient is not a candidate

All treatment regimens must have been administered for ?2 cycles unless patient is immediately allergic or intolerant to the regimen

Prior treatment with bevacizumab or other anti-vascular endothelial growth factor (VEGF) drugs

Prior treatment with TPI 287

Treatment with Enzyme-Inducing Anti-Epileptic Drugs within 2 weeks prior to Day 1

No implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment delivery

The subject has received radiation therapy:\r\n* To the thoracic cavity or gastrointestinal tract within 3 months of the first dose of study treatment\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment

The subject has started treatment with drugs used to control loss of bone mass (eg, bisphosphonates or denosumab) within 4 weeks prior to the first dose of study treatment

Subject has had prior treatment with cabozantinib

Time from last anti-tumor treatment to first radiation treatment at least 1 week

Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment

Prior treatment with radium-223

Treatment with chronic immunosuppressants

Main Inclusion Criteria:\n\n          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas\n\n          2. Chemo naïve patients with advanced/metastatic disease\n\n          3. Documented decision justifying non eligibility for surgical resection. The\n             documentation of the non eligibility for surgical resection will be reviewed by an\n             independent committee.\n\n          4. Men and women, age >18 years\n\n          5. Men and women of childbearing potential (entering the study after a confirmed\n             menstrual period and who have a negative pregnancy test), must agree to use two\n             methods (one for the patient and one for the partner) of medically acceptable forms\n             of contraception during the study and for 3 months after the last treatment intake.\n\n          6. Patient should be able and willing to comply with study visits and procedures as per\n             protocol.\n\n          7. Patient should understand, sign, and date the written voluntary informed consent form\n             at the screening visit prior to any protocol-specific procedures performed.\n\n        Main Exclusion Criteria:\n\n          1. Patient treated for a cancer other than pancreatic cancer within 5 years before\n             enrollment, with the exception of basal cell carcinoma or in situ cervical cancer\n\n          2. Any condition that the physician judges could be detrimental to subjects\n             participating in this study; including any clinically important deviations from\n             normal clinical laboratory values or concurrent medical events Previous treatment\n\n          3. Any anti-tumor therapy (any chemotherapy, radiotherapy, immunotherapy, biologic or\n             hormonal therapy) within 6 months prior to baseline\n\n          4. Treatment with any investigational agent within 4 weeks prior to baseline

Main Inclusion Criteria:\n\n          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas\n\n          2. Chemo naïve patients with advanced/metastatic disease\n\n          3. Documented decision justifying non eligibility for surgical resection. The\n             documentation of the non eligibility for surgical resection will be reviewed by an\n             independent committee.\n\n          4. Men and women, age >18 years\n\n          5. Men and women of childbearing potential (entering the study after a confirmed\n             menstrual period and who have a negative pregnancy test), must agree to use two\n             methods (one for the patient and one for the partner) of medically acceptable forms\n             of contraception during the study and for 3 months after the last treatment intake.\n\n          6. Patient should be able and willing to comply with study visits and procedures as per\n             protocol.\n\n          7. Patient should understand, sign, and date the written voluntary informed consent form\n             at the screening visit prior to any protocol-specific procedures performed.\n\n        Main Exclusion Criteria:\n\n          1. Patient treated for a cancer other than pancreatic cancer within 5 years before\n             enrollment, with the exception of basal cell carcinoma or in situ cervical cancer\n\n          2. Any condition that the physician judges could be detrimental to subjects\n             participating in this study; including any clinically important deviations from\n             normal clinical laboratory values or concurrent medical events Previous treatment\n\n          3. Any anti-tumor therapy (any chemotherapy, radiotherapy, immunotherapy, biologic or\n             hormonal therapy) within 6 months prior to baseline\n\n          4. Treatment with any investigational agent within 4 weeks prior to baseline

Any of the dosimetric treatment criteria as defined have not been met; patients who become ineligible due to inability to meet dosimetric criteria should not receive treatment as defined in this protocol and will come off the study; any subsequent adjuvant radiation will be delivered at the discretion of the treating physician

Treatment with prohibited medications less than or equal to 14 days prior to\n             treatment with rociletinib

Patients who are currently receiving treatment with any medications that have the\n             potential to prolong the QT interval and the treatment cannot be either discontinued\n             or switched to a different medication before starting rociletinib

Prior treatment with anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) monoclonal antibodies or prior CTLA-4 inhibitor or agonist or prior clusters of differentiation (CD)137 agonist or prior interferon-alfa is not allowed; other forms of prior treatment for melanoma (e.g., aldesleukin [IL-2], anti-tumor vaccine, chemotherapy) are allowed if given before the resection(s) that make(s) the patient eligible for this trial, but these must have been completed at least 4 weeks prior to randomization

Chronic treatment with steroids or any other immunosuppressant drugs

Women who are currently or planning to breastfeed during protocol treatment

Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study

Any line of treatment (first line versus beyond first line)

Prior treatment with 5-fluorouracil, irinotecan or oxaliplatin

Prior treatment with brentuximab vedotin (BV)

HCV treatment experienced or naive\r\n* HCV treatment naive: no prior exposure to any IFN, ribavirin (RBV), or other approved or experimental HCV-specific direct acting antivirals (DAA)\r\n* HCV treatment-experienced: virologic failure after treatment with polyethylene glycol (PEG)- IFN + RBV, NS3 protease inhibitor plus PEG-IFN + RBV, or regimen of sofosbuvir (SOF) +/- RBV +/- PEG-IFN regimen

Any HCV treatment which uses pegylated interferon

HCV genotype 3 treatment experienced with cirrhosis

On a prohibited medication which cannot be stopped during the duration of HCV treatment

Currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug

Patients may not be on any cytotoxic chemotherapy or hormonal treatment for breast cancer during protocol treatment; (trastuzumab is allowed in HER2 positive patients)

Previous treatment with eribulin mesylate

Prior treatment with docetaxel is allowed but not required

Prior treatment with other second line hormone therapy is allowed (e.g. flutamide, bicalutamide, nilutamide, ketoconazole, abiraterone, ARN-509); patients must be off these therapies for at least 4 weeks prior to starting treatment

Prior treatment with Xofigo (223Radium), Provenge, mitoxantrone and cabazitaxel is allowed

Subject is currently receiving treatment with a medication that has a known risk to prolong the QT interval or induce Torsades de Pointes and the treatment cannot be discontinued or switched to a different medication prior to randomization

Subjects must be on a prophylactic regimen for Pneumocystis carinii pneumonia, or agree to begin such treatment and remain on treatment until after completion of therapy and until the cluster of differentiation (CD)4 cells are greater than 200/mm^3

All biologic agents including hematopoietic growth factors must have been stopped at least 1 week prior to treatment on the study

Prior treatment with Erwinaze

Prior treatment with any cytotoxic chemotherapy for treatment of pancreatic cancer except as an adjuvant therapy; patient should not have received gemcitabine within 6 months of starting the study treatment; 5-flourouracil or radiation treatment should be received more than 4 weeks prior to receiving the study drug

Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing torsades de pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment

Chronic treatment with immunosuppressant drugs

Previous radiotherapy to the lesion(s) of interest, including prior treatment with whole-brain radiation therapy (WBRT); (prior treatment with SRS is allowed if the index lesion[s] is in a different, non-contiguous location than the previously treated lesion)

Prior treatment with dasatinib, imatinib or nilotinib

PROCEEDING TO TREATMENT WITH 5-FC:

Urgent need of treatment to prevent acute neurologic deterioration

Other non-malignant systemic disease that would preclude treatment with any of the treatment regimens or would prevent required follow-up

Have previously completed or withdrawn from this study or any other study investigating dasatinib; prior treatment with other tyrosine kinases, including afatinib, is acceptable

Patient must have been eligible for and initially randomized to Arm 1 (low dose carfilzomib), begun cycle 2 of treatment, and progressed prior to completing 12 cycles of protocol therapy

Concurrent chemotherapy (except hydroxyurea) or interleukin-2 (IL-2) therapy or anticipated need during the study treatment for 1 week after the last dose of ALT-803-hydroxyurea is permitted at any time to control blast count

No prior radionuclide treatment within 6 weeks of the first dose of study treatment

No hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 12 weeks before the first dose of study treatment

Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vemurafenib, breastfeeding must be discontinued prior to treatment day 1 of the study

No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with CPI-613; hydroxyurea and oral tyrosine kinase inhibitors being used without grade =< 2 toxicity can be taken until day 1 of therapy; patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment); patients with persisting, non-hematologic, non-infectious toxicities from prior treatment =< grade 2 are eligible, but must be documented as such

At screening, patients may be included if the largest lesion is > 1 cm or > 3 in number, if the patient has underdone treatment with surgery and/or radiation therapy and there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment

Prior treatment with trastuzumab

Current treatment or treatment within 4 weeks of screening with bisphosphonates.

History of prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blocking antibody

Subjects with an indication for AHCT for the treatment of PCM as determined by the principal investigator (PI) or lead associate investigator (LAI)\r\n* Subjects following induction treatment for PCM\r\n* Subjects with recurrent or persistent evaluable disease who have not undergone AHCT for the treatment of the PCM

Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria

Current treatment on another clinical trial; participation in non-therapeutic clinical trials is permissible

Patients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug

Patients who have relapsed from their initial doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) or similar standard treatment regimen and have not received any other chemotherapy or salvage systemic treatment

Patients must have had prior treatment with bilateral orchiectomy or androgen\n             deprivation therapy with an LHRH-blocker with evidence of treatment failure

Patients must have a Karnofsky performance status (KPS) rating of >= 60 prior to initiating treatment; patients may be enrolled at a KPS of < 60 if it is felt that the patient will have adequate opportunity to recover to a KPS >= 60 by the initiation of treatment

AT TIME OF TREATMENT:

AT TIME OF TREATMENT:

No prior treatment with LMB-2

Prior treatment with IMGN853

Prior treatment with adenovirus-based drugs

Patients with recurrent disease may have received prior treatment with carboplatin/paclitaxel but must have had a treatment free interval of > 6 months

Subject agrees not to participate in another interventional study while on treatment.

Use of T cell depleting agents for prevention or treatment of rejection at any point prior to or after enrollment in the study

Is ineligible or inappropriate for other treatment regimens known to have effective potential

Systemic strontium-89, samarium-153, rhenium-186, or rhenium-188 for bone metastases within 24 weeks prior to initiation of study treatment

Discontinuation of prior AML treatment before the start of study treatment (except hydroxyurea or other treatment to control leukocytosis) for at least 2 weeks for cytotoxic agents, or for at least 5 half-lives for non cytotoxic agents.

Prior treatment with quizartinib or participated in a prior quizartinib study.

Prior systemic treatment in the metastatic setting with Vascular epithelial growth factor(VEGF) or VEGF receptor targeted therapy

Prior treatment with imetelstat

Prior treatment with eribulin

Participants with chronic infection by Hepatitis C Virus (HCV) who are treated (successfully or treatment failure) or untreated are allowed on study. In addition, participants with successful HCV treatment are allowed as long as there are >4 weeks between achieving sustained viral response (SVR12) and start of study drug.

Prior treatment with CD19 directed agents unless CD19 expression is confirmed after completion of CD19-directed treatment

Patient is to receive bevacizumab as maintenance treatment

High-grade Ta papillary disease based on a biopsy within 8 weeks of the initial dose of study treatment. If multiple bladder biopsies are required to confirm eligibility, the last bladder biopsy to the initial dose of study treatment must be within 8 weeks. This diagnosis must be confirmed by the independent central pathology reviewer prior to subject enrollment. A subject with persistent T1 disease on the second (i.e., restaging) TURBT may be enrolled in this study only if the investigator documents the subject declines cystectomy.

History of recurrent severe urinary tract infections (UTIs) per investigator judgment. Subjects with a current UTI requiring antibiotic treatment may defer the initiation of Vicinium treatment on Day 1 until resolution of the UTI (even if this extends the screening period requirements to start of Vicinium treatment).

Treatment with immunotherapy against PCa within the previous 6 months prior to randomization

Radiographic evidence of recurrent NSCLC prior to afatinib treatment

Receipt of any experimental treatment within 30 days of start of treatment with afatinib until the end of treatment visit

For Cohort A: Has received docetaxel for mCRPC. Prior treatment with 1 other chemotherapy for mCRPC is allowed. Up to 2 second-generation hormonal manipulations (e.g., abiraterone acetate and/or enzalutamide) are allowed

For Cohort B: Has received prior treatment with either abiraterone acetate or enzalutamide (but not both) in the prechemotherapy mCRPC state. Participants in Cohort B must have received at least 4 weeks of either abiraterone or enzalutamide treatment (but not both) who failed treatment or became intolerant of the drug

For Cohort C: Has received prior treatment with abiraterone acetate in the pre-chemotherapy mCRPC state without prior enzalutamide. Participants in Cohort C must have received at least 4 weeks of abiraterone treatment who failed treatment or become intolerant of the drug.

Patient receiving an immunosuppressive treatment for GvHD treatment due to a previous allograft at the time of screening

They have other medical problems that could get much worse with this treatment.

Participant treated with any prior systemic therapy with the exception of the following:\r\n* Treatment by localized radiotherapy for a specific indication within 2 weeks of initiation of treatment\r\n* Treatment with corticosteroids, not to exceed the equivalent of 160 mg of dexamethasone over a four-week period before initiation of protocol therapy

Any prior treatment with dalantercept or any other agent targeting ALK1 pathway.

Any prior treatment with axitinib.

Patient who have had previous treatment with pazopanib or with weekly gemcitabine for recurrent or persistent disease

Patients with prior trastuzumab treatment

All other significant diseases might impair the subject's tolerance of trial treatment

Patients with gliomas who have had prior treatment with bevacizumab (Avastin) are excluded

Prior treatment with gene therapy product

CNS prophylaxis treatment must be stopped > 1 week prior to CTL019 infusion (e.g. intrathecal methotrexate) f. Radiotherapy:

Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment

Prior cabozantinib treatment.

If the subject has DLBCL, there is no curative option with conventional therapy and the prior treatment included ? 1 prior combination chemoimmunotherapy regimen.

If the subject has RS, the subject must have had ?1 prior treatment with a combination chemoimmunotherapy regimen.

Must have failed last line of treatment (refractory to last line of treatment).

Inclusion Criteria:\n\n        Subjects must satisfy the following criteria to be enrolled in the study:\n\n          1. Subject is ? 18 years of age the time of signing the informed consent form (ICF).\n\n          2. Documented diagnosis of MDS according to World Health Organization (WHO)/French\n             American British (FAB) classification that meets IPSS R classification of very low,\n             low, or intermediate risk disease, and:\n\n        Ring sideroblast ? 15% of erythroid precursors in bone marrow or ? 5% (but < 15%) if SF3B1\n        mutation is present.\n\n          -  < 5% blasts in bone marrow\n\n          -  Peripheral blood WBC count < 13,000/µL 3. Requires red blood cell RBC transfusions 4.\n             Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 5. Subjects who are\n             refractory/intolerant/ineligible to prior ESA treatment, defined as:\n\n          -  Refractory to prior Erythropoiesis- stimulating agents(ESA) treatment: documentation\n             of non-response or response that is no longer maintained to prior ESA-containing\n             regimen, either as single agent or combination (eg, with G-CSF); ESA regimen must have\n             been either recombinant human erythropoietin (rHu EPO) ? 40,000 IU/wk for at least 8\n             doses or equivalent OR darbepoetin alpha ? 500 ?g Q3W for at least 4 doses or\n             equivalent\n\n          -  Intolerant to prior ESA treatment: documentation of discontinuation of prior\n             ESA-containing regimen, either as single agent or combination (eg, with G-CSF), at any\n             time after introduction due to intolerance or an adverse event\n\n          -  ESA ineligible: low chance of response to ESA base on endogenous serum erythropoietin\n             level > 200 U/L for subjects not previously treated with ESAs\n\n        Exclusion Criteria:\n\n        The presence of any of the following will exclude a subject from enrollment:\n\n          1. Prior therapy with disease modifying agents for underlying MDS disease.\n\n          2. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)\n\n          3. MDS associated with del 5q cytogenetic abnormality\n\n          4. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury\n             or treatment with chemotherapy and/or radiation for other diseases.\n\n          5. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies,\n             or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding\n\n             - iron deficiency to be determined by serum ferritin less than or equal to 15 ug/L and\n             additional testing if clinically indicated (eg, calculated transferrin saturation\n             [iron/total iron binding capacity less than or equal to 20%] or bone marrow aspirate\n             stain for iron).\n\n          6. Prior allogeneic or autologous stem cell transplant\n\n          7. Known history of diagnosis of Acute myeloid leukemia (AML)\n\n          8. Use of any of the following within 5 weeks prior to randomization:\n\n               -  anticancer cytotoxic chemotherapeutic agent or treatment\n\n               -  corticosteroid, except for subjects on a stable or decreasing dose for ? 1 week\n                  prior to randomization for medical conditions other than MDS\n\n               -  iron-chelating agents, except for subjects on a stable or decreasing dose for at\n                  least 8 weeks prior to randomization\n\n               -  other RBC hematopoietic growth factors (eg, Interleukin-3)\n\n               -  investigational drug or device, or approved therapy for investigational use. If\n                  the half-life of the previous investigational product is known, use within 5\n                  times the half-life prior to randomization or within 5 weeks, whichever is longer\n                  is excluded.\n\n          9. Prior history of malignancies, other than MDS, unless the subject has been free of the\n             disease (including completion of any active or adjuvant treatment for prior\n             malignancy) for ? 5 years. However, subjects with the following history/concurrent\n             conditions are allowed:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix\n\n               -  Carcinoma in situ of the breast\n\n               -  Incidental histologic finding of prostate cancer (T1a or T1b using the tumor,\n                  nodes, metastasis [TNM] clinical staging system)\n\n         10. Major surgery within 8 weeks prior to randomization. Subjects must have completely\n             recovered from any previous surgery prior to randomization

Must have undergone prior treatment with ?2 treatment lines of anti-myeloma therapy and must have failed last line of treatment (refractory to last line of treatment)

Treatment with any prior gene therapy product

Prior treatment with any adoptive T cell therapy

For RCC, prior treatment with everolimus or temsirolimus

For gastric or GEJ adenocarcinoma, prior treatment with any taxane

For CRC, prior treatment with cetuximab or panitumumab

Patients must have marrow function and organ function as defined below\r\n* Note: to remain on treatment, any abnormal lab values allowed by the PI must remain stable or improve during treatment; similar off treatment rules will be applied to all patients, except the following: the grade of any abnormal laboratory (lab) value allowed by the protocol principal investigator (P.I.) at enrollment will be considered the patient’s baseline for potentially resuming therapy after modification/holding of therapy when off treatment criteria are applied

Inclusion:\n\n          1. Male or female 1 to 21 years of age at the time of consent\n\n          2. Steroid-refractory grade B-D aGvHD.\n\n               -  Steroid-refractory is defined as a failure to respond to steroid treatment, with\n                  failure to respond defined as any grade B-D (IBMTR grading) aGvHD that shows\n                  progression ? 3 days, or no improvement by 5 days of treatment with 12 mg/kg/day\n                  methylprednisolone or equivalent in subjects with lower GI or liver disease, or\n                  skin disease associated with bullae. Grade D organ involvement will be limited to\n                  skin and liver.\n\n               -  Steroid refractory may also be defined as a failure to respond to 1 mg/kg/day of\n                  methylprednisolone or equivalent in subjects with disease confined to upper GI\n                  disease or lesser degrees of skin GvHD.\n\n               -  Subjects with lack of complete response after 2 weeks of steroid treatment.\n\n          3. A Lansky scale Performance Status score ? 30.\n\n          4. Laboratory values are within the following limits, assessed within 3 days of the first\n             study treatment:\n\n               -  Absolute neutrophil count > 0.5 × 10^9/L.\n\n               -  Creatinine level < 2 times the upper limit of normal.\n\n          5. For patients with isolated upper GI symptoms, pre-Screening biopsy results to confirm\n             diagnosis of aGvHD.\n\n          6. Female patients of childbearing potential and nonsterilized males who are sexually\n             active with a female partner must be practicing highly effective, reliable, and\n             medically approved contraceptive regimen throughout their participation in the study\n             and for 3 months following the last ECP treatment. Or, for the US only, abstinence may\n             be used in place of an approved contraceptive regimen. Females of childbearing\n             potential are those who have reached the onset of menarche, or 8 years of age,\n             whichever comes first. Approved contraceptive methods for female patients of\n             childbearing potential or nonsterilized males who are sexually active with a female\n             partner are as follows:\n\n               -  Barrier methods of contraception: condom or occlusive cap (diaphragm or\n                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.\n\n               -  Established use of oral, injectable, or implanted hormonal methods of\n                  contraception.\n\n               -  Placement of an intrauterine device or intrauterine system.\n\n          7. Signed informed consent/assent is obtained before conducting any study procedures; the\n             parent, legal guardian, or legally authorized representative of a minor must also\n             provide written informed consent.\n\n        Exclusion:\n\n          1. Currently enrolled in another clinical trial for the treatment of aGvHD.\n\n          2. Use of any experimental regimens or medication(s) for aGvHD treatment.\n\n          3. Treatment with > 2.0 mg/kg/day of methylprednisolone equivalents for aGvHD within 30\n             days prior to the first study treatment.\n\n          4. Overt signs of relapse of the underlying condition.\n\n          5. Uncontrolled viral, fungal, or bacterial infection.\n\n          6. Platelet count < 20.0 × 10^9/L, despite platelet transfusion.\n\n          7. Inability to tolerate the extracorporeal volume shifts associated with ECP treatment.\n\n          8. Uncontrolled GI bleeding.\n\n          9. Veno-occlusive liver disease.\n\n         10. Life expectancy < 4 weeks.\n\n         11. Patient requires invasive ventilation or vasopressor support.\n\n         12. Known human immunodeficiency virus (HIV) or hepatitis B or C virus infection (proof of\n             seronegativity within 6 months of screening is required).\n\n         13. Known allergy or hypersensitivity to methoxsalen, Uvadex, or its excipients.\n\n         14. Known hypersensitivity and allergy to heparin and Anticoagulant Citrate Dextrose\n             Formula-A (ACD-A).\n\n         15. Co-existing photosensitive disease (e.g., porphyria, systemic lupus erythematosus,\n             albinism) or aphakia.\n\n         16. Coagulation disorders that cannot be corrected with simple transfusion.\n\n         17. Co-existing melanoma, basal cell, or squamous cell skin carcinoma.\n\n         18. Previous splenectomy.\n\n         19. White blood cell count greater than 25,000 mm3.\n\n         20. Currently being treated with any systemic immunosuppressive or biologic therapy for\n             the treatment of a medical condition other than aGvHD.\n\n         21. Female patient is breastfeeding or pregnant.\n\n         22. Any medical concerns that may pose risk to the patient.\n\n         23. Any psychological, familial, sociological, and/or geographical condition that may\n             potentially hamper compliance with the study protocol and follow-up schedule.

Concurrent treatment with any medical that prolongs QT interval and may induce torsades de pointes, and which cannot be discontinued at least 2 weeks before treatment with ASTX660. [Applies to Phase 1 only].

Hydroxyurea will not be considered a prior line of treatment.

Treatment-related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t(16;16), t(8;21), t(15;17)).

Hydroxyurea will not be considered a prior line of treatment.

Treatment-related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t(16;16), t(8;21), t(15;17)).

Histologically and/or cytologically confirmed and radiographically measurable KRAS and NRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment; in addition, for the monotherapy MET Amplified cohort, subjects must have received prior treatment with anti-EGFR therapy (either panitumumab or cetuximab)

For Combination Expansion cohort only: prior treatment with cetuximab or panitumumab

Radionuclide treatment, including yttrium-90 treatment, within 6 weeks of the first dose of study treatment

Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR

Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR

Planned treatment with biological agents within 28 days prior to receiving TheraSphere (may resume after Y-90 treatment or immediately if in control arm)

Toxicities due to prior cancer therapy that have not resolved before the initiation of study treatment, if the Investigator determines that the continuing complication will compromise the safe treatment of the patient

Treatment with chemotherapy less than or equal to (</=) 3 weeks before study treatment

Treatment with biologic therapy </= 3 weeks before study treatment

Concurrent treatment on another clinical trial; supportive care trials or non-treatment trials, e.g. quality of life (QOL), are allowed

Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances

Must have received at least 2 prior lines of therapy for the treatment of current histology; there are no treatment options available known to provide clinical benefit. Refer to National Comprehensive Cancer Network (NCCN) guidelines of each respective histology for guidance.

For the most recently received VEGFR-targeting TKI there must have been progression of disease as determined by the treating physician either (i) during treatment or (ii) within 6 mo following completion of at least 4 weeks of treatment with the TKI

Recurrent or refractory tumors with no known curative treatment options according to the judgment of the investigator.

Prior treatment with TRC105

Current treatment on another therapeutic clinical trial

History of peptic ulcer within the past 3 months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment

Prior treatment:\r\n* No radiotherapy within 90 days prior to pre-registration\r\n* No prior treatment with any anti-angiogenic agent targeting the vascular endothelial growth factor (VEGF) pathway including but not limited to bevacizumab, cediranib, vandetanib, sunitinib, pazopanib, aflibercept or sorafenib\r\n* No prior treatment with HSPPC-96 or other investigational immunotherapy\r\n* Must have received prior treatment with radiotherapy and temozolomide for histologically confirmed GBM at initial diagnosis\r\n* No tumor directed therapy for most recent progression\r\n* No prior Gliadel wafers

Prior treatment with prolifeprospan 20 with carmustine wafer.

Patients must not have received any treatment after discontinuing MEDI4736 with the following exceptions; localized palliative radiation therapy is allowed for symptom management, provided and treatment is completed >= 14 days prior to RE-TREATMENT registration; local treatment for brain metastases is allowed

Have two negative pregnancy tests as verified by the investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence2 from heterosexual contact.

Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid (ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of Cycle 1 Day 1), for Cohort C, the induction and consolidation treatment along with the first Autologous stem cell transplantation (ASCT) are allowed)

Willingness to provide pretreatment and on-treatment biopsies.

Treatment with any prior gene therapy product

For treatment-naïve subjects only:

Systemic treatment with anticancer therapy within 3 weeks before study drug treatment

Patients must have disease amenable to biopsy and must be willing to undergo a paired biopsy for correlative analyses (the first biopsy within 28 days prior to start of treatment and the second biopsy while on treatment)

Prior treatment with entrectinib.

Prior treatment for lymphoid malignancy requiring treatment for progressive disease

Ongoing medically significant adverse events from previous treatment, regardless of the time period

Prior treatment with PM01183 or trabectedin.

Post resection serum cancer antigen (CA)19-9 =< 180 units/mL AND prior to any systemic treatment

Patients who are already on prescribed treatment for paronychia who are not willing to discontinue this treatment and only use study drug (no washout period required)

Ineligible for intensification treatment due to age or significant comorbidity

Refused intensification treatment and/or ASCT

Discontinued all prior treatment for cancer at least 14 days prior to initial dose of study treatment.

Previous cytotoxic, cytostatic, hormonal, biological or immunological treatment (ESA with or without G-CSF and iron chelating therapy and hydroxyurea are allowed under certain conditions, see exclusion criterion #5) or biologic treatment for AML.

Previous treatment with ibrutinib

Subject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an investigational agent that inhibits the AR or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).

Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment

Prior treatment with pomalidomide

Must have undergone prior treatment with ?2 treatment lines of anti-myeloma therapy

Must have failed last line of treatment (refractory to last line of treatment).

Refractory to or relapsed after at least 1 prior treatment line.

Current treatment with therapeutic anticoagulants

Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment

Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.

Follicular low-grade NHL: either treatment naïve (except for France) or relapsed or refractory following at least one prior treatment. In Part 1 Dose Escalation only, in addition to follicular NHL, marginal zone B cell lymphomas: either treatment naïve or relapsed or refractory following at least one prior treatment.

Inclusion Criteria:\n\n          -  Definitive diagnosis of unresectable locally advanced or metastatic RCC with\n             clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior\n             treatment in the metastatic setting\n\n          -  Evaluable Memorial Sloan Kettering Cancer Center risk score\n\n          -  Measurable disease, as defined by RECIST v1.1\n\n          -  Karnofsky performance status greater than or equal to 70%\n\n          -  Adequate hematologic and end-organ function prior to randomization\n\n        Exclusion Criteria:\n\n        Disease-Specific Exclusions:\n\n          -  Radiotherapy for RCC within 14 days prior to treatment\n\n          -  Active central nervous system disease\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites\n\n          -  Uncontrolled hypercalcemia\n\n          -  Any other malignancies within 5 years except for low-risk prostate cancer or those\n             with negligible risk of metastasis or death\n\n        General Medical Exclusions:\n\n          -  Life expectancy less than 12 weeks\n\n          -  Participation in another experimental drug study within 4 weeks prior to treatment\n\n          -  Pregnant or lactating women\n\n          -  Known hypersensitivity to any component of atezolizumab or other study medication\n\n          -  History of autoimmune disease except controlled, treated hypothyroidism or type I\n             diabetes mellitus\n\n          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced\n             pneumonitis, or idiopathic pneumonitis\n\n          -  Positive human immunodeficiency virus test\n\n          -  Active or chronic hepatitis B or C\n\n          -  Severe infections within 4 weeks prior to treatment\n\n          -  Exposure to oral or IV antibiotics within 2 weeks prior to treatment\n\n          -  Live attenuated vaccines within 4 weeks prior to treatment, 28 days prior to\n             randomization, during treatment, or within 5 months following last dose of\n             atezolizumab\n\n          -  Significant cardiovascular disease\n\n          -  Prior allogeneic stem cell or solid organ transplantation\n\n        Exclusion Criteria Related to Medications:\n\n          -  Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic\n             T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1\n             therapeutic antibody or pathway-targeting agents\n\n          -  Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or\n             immunosuppressive agents within 2 weeks prior to treatment\n\n        Bevacizumab- and Sunitinib-Specific Exclusions:\n\n          -  History of hypertensive crisis or hypertensive encephalopathy\n\n          -  Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds

Adults with ALL in need of treatment

Prior treatment with nintedanib

Prior treatment with regorafenib

No prior treatment with GDC-0810 (allowed only during dose expansion stage)

Treatment with bisphosphonate or denosumab within 12 weeks before randomisation.

Inclusion Criteria:\n\n          -  Histologically or cytologically documented locally advanced or metastatic solid tumors\n             meeting the following study drug-specific criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n\n          -  Life expectancy greater than or equal to (>/=) 12 weeks\n\n          -  Measurable disease, as defined by RECIST v1.1\n\n          -  Adequate hematologic and end organ function as confirmed by laboratory results within\n             14 days prior to the first study treatment\n\n        Inclusion criteria specific to Arm A: Atezolizumab+ Ipilimumab\n\n          -  Escalation stage: NSCLC participants\n\n          -  Mandatory biopsy cohort: NSCLC or melanoma atezolizumab\n\n          -  Prior atezolizumab-treated cohort: participants with NSCLC or melanoma previously\n             treated with atezolizumab\n\n        Inclusion criteria specific to Arm B: Atezolizumab+ Interferon alfa-2b\n\n          -  Escalation stage: RCC or melanoma participants\n\n          -  Expansion stage: RCC or melanoma participants\n\n          -  Mandatory biopsy cohort: RCC or melanoma participants\n\n          -  Prior immunotherapy-treated cohort: participants with RCC, NSCLC, or melanoma\n             previously treated with programmed death-ligand 1 (PD-L1)/ Programmed death 1 (PD-1)\n\n        Inclusion Criteria Specific to Arm C (Atezolizumab plus PEG-Interferon Alafa-2a):\n\n          -  Cohort 1: participants with RCC\n\n          -  Cohort 2: participants who were previously treated with anti-PD-L1/PD-1 with locally\n             advanced or metastatic solid tumor (e.g., NSCLC, RCC, or melanoma)\n\n        Inclusion Criteria Specific to Arm D (Atezolizumab plus PEG?Interferon Alfa-2a\n        +Bevacizumab)\n\n          -  Cohort 1: participants with metastatic RCC with no prior line of systemic therapy for\n             metastatic disease\n\n          -  Cohorts 2-3: disease progression during or after at least one previous systemic,\n             anti-cancer treatment for locally advanced or metastatic solid tumors; participants\n             with sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic\n             lymphoma kinase (ALK) rearrangements must have failed or are intolerant to prior\n             treatment with EGFR or ALK inhibitors; participants with melanoma with actionable BRAF\n             mutations (e.g., V600) must have failed or are intolerant to prior treatment with BRAF\n             inhibitors\n\n        Inclusion Criteria Specific to Arm E (Atezolizumab +Obinutuzumab)\n\n        - R/M HNSCC participants with at least one prior line of systemic therapy\n\n        Inclusion Criteria Specific to prior Anti?PD-L1/PD-1 Treated Cohorts:\n\n          -  No permanent discontinuation of atezolizumab or other immunotherapies due to a\n             treatment-related adverse event\n\n          -  Recovery from all immunotherapy-related adverse events to Grade less than or equal to\n             (?) 1 or baseline at the time of consent\n\n        Exclusion Criteria:\n\n        General Medical Exclusions:\n\n          -  Pregnant and lactating women\n\n          -  Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3\n             weeks prior to initiation of study treatment, with the following exception: (1)\n             hormone-replacement therapy or oral contraceptives; (2) tyrosine kinase inhibitors\n             (TKIs) that have been discontinued greater than (>) 7 days prior to Cycle 1, Day 1,\n             baseline scans must be obtained after discontinuation of prior TKIs\n\n          -  Investigational therapy within 28 days prior to initiation of study treatment\n\n          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to\n             chimeric or humanized antibodies or fusion proteins\n\n          -  Known hypersensitivity or allergy to Chinese hamster ovary cell products or any\n             component of the atezolizumab formulation\n\n          -  History of or active autoimmune disease\n\n          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced\n             pneumonitis, organizing pneumonia, risk of pulmonary toxicity, or evidence of active\n             pneumonitis on screening chest computed tomography (CT) scan\n\n          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation\n\n          -  History of human immunodeficiency virus (HIV)\n\n          -  Participants with active hepatitis B\n\n          -  Participants with active hepatitis C\n\n          -  Participants with active tuberculosis\n\n          -  Participants with a history of confirmed progressive multifocal leukoencephalopathy\n\n          -  Any serious medical condition, physical examination finding, or abnormality in\n             clinical laboratory tests that, in the investigator's judgment, precludes the\n             participant's safe participation in and completion of the study\n\n        Cancer-Specific Exclusions:\n\n          -  Active or untreated central nervous system (CNS) metastases, as determined by CT or\n             magnetic resonance imaging (MRI) evaluation during screening and prior radiographic\n             assessments\n\n          -  Spinal cord compression not definitively treated with surgery and/or radiation or\n             previously diagnosed and treated spinal cord compression without evidence that disease\n             has been clinically stable for >/= 2 weeks prior to screening\n\n          -  Leptomeningeal disease\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures (once monthly or more frequently); participants with indwelling\n             catheters are allowed.\n\n          -  Uncontrolled tumor-related pain\n\n          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of\n             bisphosphonate therapy or denosumab\n\n          -  History of other malignancy within 2 years prior to screening, except for\n             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,\n             Stage I uterine cancer, localized prostate cancer treated with curative intent, ductal\n             carcinoma in situ treated surgically with curative intent, or other cancers with a\n             similar outcome\n\n        Exclusion Criteria Related to Medications:\n\n          -  Prior treatment with cluster of differentiation 137 (CD137) agonists or immune\n             checkpoint blockade therapies (Note: Participants enrolled in the prior\n             anti?PD-L1/PD-1 treated cohorts with melanoma may have received prior anti-cytotoxic\n             T-lymphocyte-associated protein 4 treatment or other immunotherapies)\n\n          -  Treatment with systemic immunostimulatory agents within four weeks or five half-lives\n             of the drug, whichever is shorter, prior to Cycle 1, Day 1\n\n          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1,\n             Day 1 (the use of inhaled corticosteroids and mineralocorticoids is allowed)\n\n        Exclusion Criteria Specific to Interferon Alpha Therapy (Arms B?D):\n\n          -  History of depression, suicidal ideation or behavior, bipolar disorder, or psychosis\n\n          -  Hypersensitivity to interferon alpha or any component of the product\n\n        Exclusion Criteria Specific to Bevacizumab (Arm D)\n\n          -  Inadequately controlled hypertension\n\n          -  Prior history of hypertensive crisis or hypertensive encephalopathy\n\n          -  Significant vascular disease within 6 months prior to Day 1\n\n          -  History of hemoptysis\n\n          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of\n             therapeutic anticoagulation)\n\n          -  History of tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal\n             abscess within 6 months prior to Day 1\n\n          -  Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine\n             parenteral hydration, parenteral nutrition, or tube feeding\n\n          -  Evidence of abdominal free air that is not explained by paracentesis or recent\n             surgical procedure\n\n          -  Proteinuria, as demonstrated by urine dipstick or > 1.0 gram of protein in a 24-hour\n             urine collection\n\n          -  Metastatic disease that involves major airways or blood vessels, or centrally located\n             mediastinal tumor masses of large volume\n\n        Exclusion Criteria Specific Obinutuzumab (Arm E)\n\n          -  Hypersensitivity to obinutuzumab\n\n          -  Prior treatment with obinutuzumab

Inclusion Criteria:\n\n        - Subjects must satisfy the following criteria to be enrolled in the study:\n\n          1. Adults (age ? 18 years at the time of signing the ICD) with documented diagnosis of MM\n             and measurable disease (serum M-protein ? 0.5 g/dL or urine M-protein ? 200 mg/24\n             hours).\n\n          2. Subjects enrolling in Cohort A (Pom+LD-dex) must have received 2 prior treatment lines\n             of anti-myeloma therapy. Subjects enrolling in Cohort B (Pom+Dara+LD-dex) must have\n             received 1 or 2 prior treatment lines of anti-myeloma therapy.\n\n          3. All subjects must have received prior treatment with LEN or a LEN-containing regimen\n             for at least 2 consecutive cycles as the most recent treatment regimen.\n\n          4. All subjects must have documented disease progression during or after their last\n             antimyeloma therapy.\n\n          5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status\n             score of 0, 1, or 2.\n\n          6. Subjects must understand and voluntarily sign an ICD prior to any study related\n             assessments/procedures being conducted.\n\n          7. Subjects must be able to adhere to the study visit schedule and other protocol\n             requirements.\n\n          8. All subjects must provide an adequate bone marrow sample at screening that\n             definitively evaluates the presence or absence of myelodysplastic changes.\n\n          9. Females with child-bearing potential (FCBP†) must agree to use 2 reliable forms of\n             contraception* simultaneously or practice complete abstinence from heterosexual\n             contact for at least 28 days before starting study drug, while participating in the\n             study (including during dose interruptions), and for at least 28 days after study\n             treatment discontinuation and must agree to regular pregnancy testing during this\n             timeframe. For subjects enrolled in Cohort B, pregnancy prevention and testing will\n             continue until 3 months after last dose of daratumumab.\n\n         10. Females must agree to abstain from breastfeeding during study participation and 28\n             days after study drug discontinuation. Female subjects enrolled in Cohort B must agree\n             to abstain from breastfeeding and donating eggs during study participation and until 3\n             months after last dose of daratumumab.\n\n         11. Males must agree to use a latex condom during any sexual contact with FCBP while\n             participating in the study and for 28 days following discontinuation from this study,\n             even if he has undergone a successful vasectomy. Male subjects enrolled in Cohort B\n             must agree to use a latex condom during any sexual contact with FCBP while\n             participating in the study and until 3 months after last dose of daratumumab.\n\n         12. Males must also agree to refrain from donating semen or sperm during the treatment\n             phase and for 28 days after discontinuation from this study treatment. Male subjects\n             enrolled in Cohort B must also agree to refrain from donating semen or sperm during\n             the treatment phase and until 3 months after last dose of daratumumab.\n\n         13. All subjects must agree to refrain from donating blood while on study therapy and for\n             28 days after discontinuation from this study treatment.\n\n         14. All subjects must agree not to share medication.\n\n        Exclusion Criteria:\n\n        The presence of any of the following will exclude a subject from study enrollment:\n\n          1. Any of the following laboratory abnormalities:\n\n               -  Absolute neutrophil count < 1,000/?L\n\n               -  Platelet count < 75,000/?L for subjects in whom < 50% of bone marrow nucleated\n                  cells are plasma cells; or a platelet count < 30,000/?L for subjects in whom ?\n                  50% of bone marrow nucleated cells are plasma cells.\n\n               -  Severe renal impairment (Creatinine Clearance [CrCl] < 30 mL/min) requiring\n                  dialysis.\n\n               -  Corrected serum calcium > 11.5 mg/dL (> 2.8 mmol/L)\n\n               -  Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior red blood cell transfusion or\n                  recombinant human erythropoietin use is permitted)\n\n               -  Serum SGOT/AST or SGPT/ALT > 3.0 x the upper limit of normal (ULN)\n\n               -  Serum total bilirubin > 2.0 mg/dL (34.2 ?mol/L); or > 3.0 x ULN for subjects with\n                  hereditary benign hyperbilirubinemia\n\n          2. Prior history of malignancies, other than MM, unless the subject has been free of the\n             disease for ? 5 years. Allowed exceptions include the following:\n\n               -  Basal or squamous cell carcinoma of the skin\n\n               -  Carcinoma in situ of the cervix or breast\n\n               -  Incidental histological finding of prostate cancer (TNM [tumor, nodes,\n                  metastasis] stage of T1a or T1b)\n\n          3. Previous therapy with pomalidomide or daratumumab\n\n          4. Hypersensitivity to thalidomide, LEN, or dex (this includes ? Grade 3 rash during\n             prior thalidomide or LEN therapy)\n\n          5. Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem\n             cell transplant less than 12 months prior to initiation of study treatment and who\n             have not discontinued immunosuppressive treatment for at least 4 weeks prior to\n             initiation of study treatment and are currently dependent on such treatment.\n\n          6. Subjects with any one of the following:\n\n               -  Congestive heart failure (NY Heart Association Class III or IV)\n\n               -  Myocardial infarction within 12 months prior to starting study treatment\n\n               -  Unstable or poorly controlled angina pectoris, including Prinzmetal's variant\n                  angina pectoris\n\n          7. Subjects who received any of the following within 14 days of initiation of study\n             treatment:\n\n               -  Major surgery (kyphoplasty is not considered major surgery)\n\n               -  Use of any anti-myeloma drug therapy\n\n          8. Use of any investigational agents within 28 days or 5 half-lives (whichever is longer)\n             of treatment, unless approved by the sponsor.\n\n          9. Incidence of gastrointestinal disease that may significantly alter the absorption of\n             Pomalidomide.\n\n         10. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment\n\n         11. Any serious medical condition, laboratory abnormality, or psychiatric illness that\n             would prevent the subject from signing the ICD\n\n         12. Pregnant or breastfeeding females\n\n         13. Known human immunodeficiency virus (HIV) positivity; active infectious hepatitis A, B,\n             or C; or chronic hepatitis B or C\n\n         14. For subjects enrolling in Cohort B - Subject has known allergies, hypersensitivity to\n             mannitol, corticosteroids, monoclonal antibodies or human proteins, or their\n             excipients (refer to the Daratumumab IB), or known sensitivity to mammalian-derived\n             products.

Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician

Have a clinical indication for treatment as determined by the investigator

No prior treatment except patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids, cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome) and/or a single dose of intrathecal methotrexate (MTX) at the time of the pre-treatment diagnostic lumbar puncture

No prior treatment with cetuximab

Patients must not have used cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 8 weeks of randomization

Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.

Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator.

Patients who do not meet parent protocol criteria to continue study treatment.

No prior systemic treatment for ES-SCLC

Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator

Prior treatment with sorafenib or tivozanib.

Subject must be deriving benefit from continued treatment without any persistent intolerable toxicity from continued treatment of ASP2215.

Subject agrees not to participate in another interventional study while on treatment.

Receipt of any radiotherapy or hormonal therapy for cancer treatment within 30 days prior to first dose of study treatment

More than one chemotherapeutic regimen given for R/M disease. Prior treatment with immunotherapy is allowed.

Prior use of cetuximab in the R/M disease treatment setting (except cetuximab during curative radiotherapy)

Prior treatment with either BBI608 or BBI503

Patients who have had previous treatment with:

Previous cancer treatment contraindicates this protocol therapy.

Prior treatment with fulvestrant

Prior treatment with radiotherapy is allowed.

Patients may begin BBI608 on a date determined by the investigator and medical monitor for the sponsor after a minimum of 14 days since last receiving anti-cancer treatment which did not include BBI608, provided that all treatment-related adverse events have resolved or have been deemed irreversible (except for alopecia).

Prior irinotecan treatment

Previous treatment with Samarium-153 or Strontium-89.

Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment

The subject with a previous history of a non-invasive carcinoma is eligible if he/she has had successful curative treatment any time prior to Screening.

Inclusion Criteria:\n\n        All Participants:\n\n          -  Confirmed diagnosis of multiple myeloma (MM)\n\n          -  Measurable disease\n\n          -  Archival or newly obtained bone marrow material available. In addition, for\n             participants in the United States (US) and Canada, able to provide newly obtained bone\n             marrow aspirate for biomarker analysis.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Adequate organ function\n\n          -  Female participants of childbearing potential must be willing to use 2 methods of\n             birth control or be surgically sterile, or abstain from heterosexual activity for the\n             course of the study through 120 days after the last dose of study treatment\n\n          -  Male participants must agree to use a latex condom during sexual contact with females\n             of childbearing potential even if they have had a successful vasectomy starting with\n             the first dose of study treatment through 120 days after the last dose of study\n             treatment\n\n          -  Able to swallow capsules and able to take or tolerate oral medications on a continuous\n             basis\n\n        Dose Determination Arm, Dose Confirmation Arm and Cohort 1 Participants:\n\n          -  Failed at least 2 lines of prior therapy (e.g. bortezomib or carfilzomib and either\n             thalidomide, pomalidomide, or lenalidomide)\n\n          -  Prior anti-MM treatments must have included an immunomodulatory (IMiD) treatment\n             (lenalidomide, pomalidomide or thalidomide) AND proteasome inhibitor (bortezomib or\n             carfilzomib) alone or in combination and participant must have failed therapy with an\n             IMiD OR proteasome inhibitor\n\n          -  Must agree to follow the regional requirements for lenalidomide counseling, pregnancy\n             testing, and birth control; willing and able to comply with the regional requirements\n             (for example, periodic pregnancy tests and safety labs)\n\n        Cohort 2 Participants:\n\n          -  MM with relapsing or refractory disease at study entry\n\n          -  Received prior treatment with 1 to 3 lines for MM\n\n          -  Achieved a partial response to at least one prior regimen (defined as ?50% decrease in\n             tumor burden)\n\n          -  Left ventricular ejection fraction of at least 40%\n\n        Exclusion Criteria:\n\n        All Participants:\n\n          -  Currently participating in and receiving study therapy or has participated in a study\n             of an investigational agent or using an investigational device within 4 weeks of the\n             first dose of study treatment\n\n          -  History of repeated infections; primary amyloidosis; hyperviscosity; plasma cell\n             leukemia; polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and\n             skin changes (POEMS) syndrome or Waldenström's macroglobulinemia\n\n          -  Diagnosis of immunosuppressive disorder or on any other immunosuppressive therapy\n             within 7 days prior to the first dose of study treatment\n\n          -  Received a prior monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who\n             has not recovered (i.e. ? Grade 1 or at baseline) from a baseline AE or a Grade 1 AE\n             associated with agents administered more than 4 weeks earlier\n\n          -  Prior anti-MM therapy (including dexamethasone), targeted small molecule therapy, or\n             radiation therapy within 2 weeks prior to study Day 1 or not recovered from AEs due to\n             a previously administered agent\n\n          -  An additional malignancy that is progressing or requires active treatment within the\n             last 5 years\n\n          -  Clinically active central nervous system (CNS) involvement\n\n          -  Active autoimmune disease or a documented history of autoimmune disease, or a syndrome\n             that requires systemic steroids or immunosuppressive agents\n\n          -  Has a history of (non-infectious) pneumonitis that required steroids or current\n             pneumonitis\n\n          -  Active infection requiring intravenous systemic therapy\n\n          -  Known psychiatric or substance abuse disorders that would interfere with cooperation\n             with the requirements of the study\n\n          -  Pregnant or breastfeeding, or expecting to conceive or father children within the\n             projected duration of the study, starting with the pre-screening or screening visit\n             through 120 days after the last dose of study treatment\n\n          -  Prior therapy with an anti-programmed cell death (PD)-1, anti-PD ligand 1\n             (anti-PD-L1), anti-PD-L2, anti-CD137 antibody, or anti-Cytotoxic\n             T-lymphocyte-associated antigen-4 (CTLA-4) agent\n\n          -  Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C\n             Virus (HCV) infection\n\n          -  Clinically significant coagulopathy\n\n          -  Known symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia\n\n          -  Has had or is planning for allogeneic stem cell transplant\n\n          -  Autologous stem cell transplant within 12 weeks before the first infusion\n\n          -  History of Grade 4 rash associated with thalidomide treatment\n\n          -  Known hypersensitivity to thalidomide, lenalidomide or pomalidomide\n\n          -  Received a live vaccine within 30 days of planned start of study treatment\n\n        Dose Determination Arm, Dose Confirmation Arm and Cohort 1 Participants:\n\n          -  Known gastrointestinal disease that may significantly alter the absorption of\n             lenalidomide\n\n          -  Unable or unwilling to undergo antithrombotic prophylactic treatment\n\n        Cohort 2 Participants:\n\n          -  Smoldering MM (SMM), monoclonal gammopathy of undetermined significance (MGUS), plasma\n             cell leukemia or Waldenström's macroglobulinemia\n\n          -  Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to the\n             first dose of study treatment\n\n          -  Myocardial infarction within 4 months prior to randomization, New York Heart\n             Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of\n             severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick\n             sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3\n             conduction system abnormalities unless participant has a pacemaker.\n\n          -  Known history of allergy to CAPTISOL® (a cyclodextrin derivative used to solubilize\n             carfilzomib)\n\n          -  Hypersensitivity to carfilzomib, bortezomib, boron, or mannitol\n\n          -  Contraindication to any of the required concomitant drugs or supportive treatments,\n             including hypersensitivity to all anticoagulation and antiplatelet options, antiviral\n             drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment\n\n          -  Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to the first\n             dose of study treatment\n\n          -  Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14\n             days prior to the first dose of study treatment

Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Subjects must have discontinued use of such agents prior to beginning study treatment.

Treatment with a therapeutic antibody less than 4 weeks before the first dose of CPI-0610. A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of CPI-0610 may be permitted in patients with rapidly progressive or aggressive subtypes of lymphoma following discussion with the medical monitor.

Prior treatment with rigosertib;

EXCLUSION FOR TREATMENT: Prior neurologic toxicity to previous immunotherapy

Current treatment on another therapeutic clinical trial

History of peptic ulcer disease within 3 months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment

Prior treatment with lenalidomide

Treatment with other locoregional therapies (other than study treatment) has not been planned for the duration of the clinical study period

Prior yttrium-90 microsphere treatment to the liver

Prior treatment with transarterial chemoembolization (TACE) or bland embolization >2 months prior to randomization and must have been applied to a treatment field and/or lobe not targeted for treatment under this protocol

Treatment for the studied cancer within 28 days prior to initiation of study treatment

Prior treatment with plitidepsin.

Symptomatic arrhythmia (excluding grade ? 2 anemia-related sinusal tachycardia) or any arrhythmia requiring ongoing treatment, and/or prolonged grade ? 2 QT-QTc, or presence of unstable atrial fibrillation. Patients with stable atrial fibrillation on treatment are allowed provided they do not meet any other cardiac or prohibited drug exclusion criterion.

Del(5q) karyotype unless treatment with lenalidomide has failed. Failure is defined as either: 1) having received at least 3 months of lenalidomide treatment without RBC transfusion benefit (International Working Group [IWG] 2006); 2) progression or relapse after hematologic improvement with lenalidomide (IWG 2006); 3) discontinuation of lenalidomide due to toxicity; or 4) unable to receive lenalidomide due to a contraindication. Source documentation for lenalidomide treatment failure must be verified by the sponsor

Patients must have progressed on or within 60 days after end of previous therapy before to study entry, i.e., refractory to the last line of treatment.

All patients who disagree to refrain from donating blood while on study treatment and for 4 weeks after discontinuation from this study treatment.

Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.

Treatment Naive MCL patients requiring treatment with no exposure to prior therapies. Relapsed/Refractory patients defined as disease relapsed or been refractory to ? 1 prior therapies for MCL and requiring further treatment. Patient who discontinued any prior treatment for MCL for tolerability reasons can also be enrolled.

Have been informed of other treatment options

Prior treatment with lenvatinib.

Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment)

Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec

Requires intermittent or chronic treatment with antiherpetic drugs, except for topical agents

Has progressed on more than 2 prior treatment regimens for acute GVHD.

Subjects must have received prior treatment with a lenalidomide-containing regimen for at least 2 consecutive cycles (full therapeutic dose) and must have been deemed as relapsed, refractory, or intolerant. Refractory is defined as progressing on-treatment or within 60 days of the last dose.

Previous treatment with decitabine or azacitidine or other hypomethylating agent.

Live vaccines should ideally not be administered to any patients undergoing treatment with chemotherapy or immunotherapy, but if need be, they should be administered >4 months prior to the initiation of treatment or >4 months after the completion of all treatment

Concomitant treatment with:

For participants enrolled in the safety run-in phase: lymphoma classified as either relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen or previously untreated Grade 1, 2, or 3a FL that requires treatment

For women who are not postmenopausal or surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than [<] 1 percent [%] per year during the treatment period and for at least 18 months after the last dose of study treatment for participants in the Atezo-G-benda and Atezo-G-CHOP treatment groups or for at least 12 months after the last dose of study treatment for participants in the Atezo-R-CHOP treatment group

Previous systemic chemotherapy is permitted if administered as induction treatment (=< 2 cycles) before definitive chemoradiotherapy for early stage disease and there is no evidence of tumor progression during or after treatment completion

Did not receive any anti-cancer treatment since the last dose of MK-3475

Patients must discontinue treatment with H2-blockers (cimetidine, ranitidine, etc.) prior to beginning protocol therapy

Vaccinated with any of the vaccines planned for administration in the trial within 8 weeks of starting treatment on the study

Prior treatment with a therapeutic agent targeting CD19 and/or CD3

A clinical indication for treatment as determined by the investigator

Ongoing infection that requires parenteral treatment with antibiotics

Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.

Previous antiangiogenic treatment

History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine) within the last year

Any progression during treatment if the lenalidomide and dexamethasone regimen was the most recent line of therapy.

Any prior treatment with carfilzomib

Prior treatment with carfilzomib or oprozomib

More than one previous treatment line with erlotinib, gefitinib or afatinib

Previous first line treatment with at least standard dose of radiotherapy (total dose >= 54 gray [Gy]) and temozolomide

Has prior treatment with Gliadel (carmustine) unless it was administered as first line treatment and at least 3 months prior to study treatment

Current treatment for active connective tissue disorders, such as lupus or scleroderma

Uncontrolled infection; to be eligible, patients receiving treatment for an infection (antibiotic, antifungal or antiviral treatment) must be afebrile (< 38.3 degrees Celsius [C]) and without hemodynamic instability or dyspnea from pneumonia for > 48 hours (hrs) prior to the start of induction therapy

Any cytotoxic chemotherapy,or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen within 14 days of the first dose of study treatment

Current treatment with steroids

Prior treatment with temozolomide, dacarbazine or procarbazine

Have chosen a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment options

Currently requiring any type of full-dose anti-coagulation treatment, systemic administration of antibiotics or chronic administration of anti-viral agents

Is receiving concomitant treatment with drugs that may interact with capecitabine

Prior treatment with bleomycin

Prior treatment with systemic steroids within 4 weeks prior to lymphodepletion (except for physiologic replacement doses for adrenal insufficiency, premedication for contrast allergies for scans, and for drug fever related to targeted therapy)